P809 PATIENTS WITH T2DM ACCOMPANYING SEVERE DEGREE OF NAFLD ASSESSED BY CONTROLLED ATTENUATION PARAMETER USING FIBROSCAN (English)
- New search for: Chon, Y. E.
- New search for: Kim, K.
- New search for: Jung, K. S.
- New search for: Kim, S. U.
- New search for: Park, J. Y.
- New search for: Kim, D. Y.
- New search for: Ahn, S. H.
- New search for: Chon, C. Y.
- New search for: Han, K. H.
- New search for: Chon, Y. E.
- New search for: Kim, K.
- New search for: Jung, K. S.
- New search for: Kim, S. U.
- New search for: Park, J. Y.
- New search for: Kim, D. Y.
- New search for: Ahn, S. H.
- New search for: Chon, C. Y.
- New search for: Han, K. H.
In:
JOURNAL OF HEPATOLOGY
;
60
, 1
;
S340-S341
;
2014
-
ISSN:
- Article (Journal) / Print
-
Title:P809 PATIENTS WITH T2DM ACCOMPANYING SEVERE DEGREE OF NAFLD ASSESSED BY CONTROLLED ATTENUATION PARAMETER USING FIBROSCAN
-
Contributors:Chon, Y. E. ( author ) / Kim, K. ( author ) / Jung, K. S. ( author ) / Kim, S. U. ( author ) / Park, J. Y. ( author ) / Kim, D. Y. ( author ) / Ahn, S. H. ( author ) / Chon, C. Y. ( author ) / Han, K. H. ( author )
-
Published in:JOURNAL OF HEPATOLOGY ; 60, 1 ; S340-S341
-
Publisher:
- New search for: Elsevier Science B.V., Amsterdam.
-
Publication date:2014-01-01
-
Size:S340-S341
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.3623
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.3623 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 60, Issue 1
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
FocusFriedman, S. L. et al. | 2014
- 3
-
Journal of Hepatology, an international top rank journalSamuel, D. et al. | 2014
- 4
-
Go EastPeck-Radosavljevic, M. et al. | 2014
- 6
-
Victory and defeat at Heraclea – Treating hepatitis C infection following liver transplantation with telaprevir and boceprevirCharlton, M. / Dick, T. et al. | 2014
- 9
-
Hepatic CD141+IFNλ+ DC subset: One against all?Wegscheid, C. / Karimi, K. / Tiegs, G. et al. | 2014
- 12
-
Time to say goodbye to the drug or the model? – Why do drugs fail to live up to their promise in bile duct ligated mice?Fickert, P. et al. | 2014
- 16
-
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirinAndriulli, A. / Di Marco, V. / Margaglione, M. / Ippolito, A. M. / Fattovich, G. / Smedile, A. / Valvano, M. R. / Calvaruso, V. / Gioffreda, D. / Milella, M. et al. | 2014
- 22
-
HLA-B⁎27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitopeNitschke, K. / Barriga, A. / Schmidt, J. / Timm, J. r. / Viazov, S. / Kuntzen, T. / Kim, A. Y. / Lauer, G. M. / Allen, T. M. / Gaudieri, S. et al. | 2014
- 30
-
Hepatitis C virus modulates lipid regulatory factor Angiopoietin-like 3 gene expression by repressing HNF-1α activityFoka, P. / Karamichali, E. / Dalagiorgou, G. / Serti, E. / Doumba, P. P. / Pissas, G. / Kakkanas, A. / Kazazi, D. / Kochlios, E. / Gaitanou, M. et al. | 2014
- 39
-
Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disordersFransen van de Putte, D. E. / Makris, M. / Fischer, K. / Yee, T. T. / Kirk, L. / van Erpecum, K. J. / Patch, D. / Posthouwer, D. / Mauser-Bunschoten, E. P. et al. | 2014
- 46
-
Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: Results from the ANRS CO13 HEPAVIH cohort studyCarrieri, M. P. / Lions, C. / Sogni, P. / Winnock, M. / Roux, P. / Mora, M. / Bonnard, P. / Salmon, D. / Dabis, F. o. / Spire, B. et al. | 2014
- 54
-
Reduction of HBV replication prolongs the early immunological response to IFNα therapyTan, A. T. / Hoang, L. T. / Chin, D. / Rasmussen, E. / Lopatin, U. / Hart, S. / Bitter, H. / Chu, T. / Gruenbaum, L. / Ravindran, P. et al. | 2014
- 62
-
Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapyPapatheodoridis, G. / Goulis, J. / Manolakopoulos, S. / Margariti, A. / Exarchos, X. / Kokkonis, G. / Hadziyiannis, E. / Papaioannou, C. / Manesis, E. / Pectasides, D. et al. | 2014
- 69
-
Multiparametric magnetic resonance for the non-invasive diagnosis of liver diseaseBanerjee, R. / Pavlides, M. / Tunnicliffe, E. M. / Piechnik, S. K. / Sarania, N. / Philips, R. / Collier, J. D. / Booth, J. C. / Schneider, J. E. / Wang, L. M. et al. | 2014
- 78
-
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experienceCoilly, A. / Roche, B. / Dumortier, J. r. / Leroy, V. / Botta-Fridlund, D. / Radenne, S. / Pageaux, G. P. / Si-Ahmed, S. N. / Guillaud, O. / Antonini, T. M. et al. | 2014
- 87
-
Resistin and visfatin in steatotic and non-steatotic livers in the setting of partial hepatectomy under ischemia-reperfusionElias-Miró, M. / Mendes-Braz, M. / Cereijo, R. / Villarroya, F. / Jiménez-Castro, M. n. / Gracia-Sancho, J. / Guixé-Muntet, S. / Massip-Salcedo, M. / Domingo, J. C. / Bermudo, R. et al. | 2014
- 96
-
Hirmi Valley liver disease: A disease associated with exposure to pyrrolizidine alkaloids and DDTRobinson, O. / Want, E. / Coen, M. / Kennedy, R. / van den Bosch, C. / Gebrehawaria, Y. / Kudo, H. / Sadiq, F. / Goldin, R. D. / Hauser, M. L. et al. | 2014
- 103
-
Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growthLing, C. C. / Ng, K. T. / Shao, Y. / Geng, W. / Xiao, J. W. / Liu, H. / Li, C. X. / Liu, X. B. / Ma, Y. Y. / Yeung, W. H. et al. | 2014
- 110
-
Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary teamDyson, J. / Jaques, B. / Chattopadyhay, D. / Lochan, R. / Graham, J. / Das, D. / Aslam, T. / Patanwala, I. / Gaggar, S. / Cole, M. et al. | 2014
- 118
-
The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACEHucke, F. / Sieghart, W. / Pinter, M. / Graziadei, I. / Vogel, W. / Müller, C. / Heinzl, H. / Waneck, F. / Trauner, M. / Peck-Radosavljevic, M. et al. | 2014
- 127
-
The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinomaZeng, S. S. / Yamashita, T. / Kondo, M. / Nio, K. / Hayashi, T. / Hara, Y. / Nomura, Y. / Yoshida, M. / Oishi, N. et al. | 2014
- 135
-
CD141+ myeloid dendritic cells are enriched in healthy human liverKelly, A. / Fahey, R. / Fletcher, J. M. / Keogh, C. / Carroll, A. G. / Siddachari, R. / Geoghegan, J. / Hegarty, J. E. / Ryan, E. J. / O’Farrelly, C. et al. | 2014
- 143
-
The intrahepatic signalling niche of hedgehog is defined by primary cilia positive cells during chronic liver injuryGrzelak, C. A. / Martelotto, L. G. / Sigglekow, N. D. / Patkunanathan, B. / Ajami, K. / Calabro, S. R. / Dwyer, B. J. / Tirnitz-Parker, J. E. / Watkins, D. N. / Warner, F. J. et al. | 2014
- 152
-
AMPKα1 controls hepatocyte proliferation independently of energy balance by regulating Cyclin A2 expressionMerlen, G. g. / Gentric, G. r. / Celton-Morizur, S. v. / Foretz, M. / Guidotti, J. E. / Fauveau, V. r. / Leclerc, J. / Viollet, B. / Desdouets, C. et al. | 2014
- 160
-
Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated miceWeerachayaphorn, J. / Luo, Y. / Mennone, A. / Soroka, C. J. / Harry, K. / Boyer, J. L. et al. | 2014
- 167
-
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver diseaseCusi, K. / Chang, Z. / Harrison, S. / Lomonaco, R. / Bril, F. / Orsak, B. / Ortiz-Lopez, C. / Hecht, J. / Feldstein, A. E. / Webb, A. et al. | 2014
- 175
-
A bidirectional crosstalk between iNKT cells and adipocytes mediated by leptin modulates susceptibility for T cell mediated hepatitisVenken, K. / Seeuws, S. / Zabeau, L. / Jacques, P. / Decruy, T. / Coudenys, J. / Verheugen, E. / Windels, F. / Catteeuw, D. / Drennan, M. et al. | 2014
- 183
-
Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failureMutanen, A. / Heikkilä, P. i. / Lohi, J. / Raivio, T. / Jalanko, H. / Pakarinen, M. P. et al. | 2014
- 191
-
Is there sufficient evidence to recommend antiviral therapy in hepatitis C?van der Meer, A. J. / Wedemeyer, H. / Feld, J. J. / Hansen, B. E. / Manns, M. P. / Zeuzem, S. / Janssen, H. L. et al. | 2014
- 197
-
Pathological bacterial translocation in liver cirrhosisWiest, R. / Lawson, M. / Geuking, M. et al. | 2014
- 210
-
Autoimmune liver disease, autoimmunity and liver transplantationCarbone, M. / Neuberger, J. M. et al. | 2014
- 224
-
Genetics of hepatocellular carcinoma: The next generationNault, J. C. / Zucman-Rossi, J. et al. | 2014
- 227
-
Antisense therapy for hepatitis C virus infectionde Jong, Y. P. / Jacobson, I. M. et al. | 2014
- 229
-
Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinomaFelga, G. / Salvalaggio, P. R. / de Rezende, M. B. / de Almeida, M. D. et al. | 2014
- 230
-
Reply to: “Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma”Sposito, C. / Mazzaferro, V. et al. | 2014
- 231
-
Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infectionsClaassen, M. A. / Janssen, H. L. / de Knegt, R. J. / Boonstra, A. et al. | 2014
- 232
-
Reply to: “Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections”Langhans, B. / Spengler, U. et al. | 2014
- 234
-
From the CUPIC study: Great times are not coming (?)Carvalho-Filho, R. J. / Narciso-Schiavon, J. n. / Schiavon, L. L. et al. | 2014
- 235
-
Reply to: From the CUPIC study: Great times are not coming (?)Carrat, F. / Barthe, Y. / Hezode, C. / Fontaine, H. / Bronowicki, J. P. et al. | 2014
- 237
-
Corrigendum to: “Challenges in cancer vaccine development for hepatocellular carcinoma” [J Hepatol 2013;59:897–903]Buonaguro, L. / Petrizzo, A. / Tagliamonte, M. / Tornesello, M. L. / Buonaguro, F. M. et al. | 2014
- 238
-
Corrigendum to: “Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C” [J Hepatol 2013;59:696–700]Squadrito, G. / Cacciola, I. / Alibrandi, A. / Pollicino, T. / Raimondo, G. et al. | 2014
- I
-
Guide for Authors| 2014
- S1
-
O2 OBETICHOLIC ACID, A FARNESOID-X RECEPTOR AGONIST, REDUCES BACTERIAL TRANSLOCATION AND RESTORES INTESTINAL PERMEABILITY IN A RAT MODEL OF CHOLESTATIC LIVER DISEASEVerbeke, L. / Farre, R. / Covens, K. / Verbinnen, B. / Vanuytsel, T. / Vander Elst, I. / Windmolders, P. / Verhaegen, J. / Komuta, M. / Roskams, T. et al. | 2014
- S2
-
O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDYWedemeyer, H. / Yurdaydin, C. / Ernst, S. / Caruntu, F. A. / Curescu, M. G. / Yalcin, K. / Akarca, U. S. / Gürel, S. / Zeuzem, S. / Erhardt, A. et al. | 2014
- S3
-
O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCEGane, E. J. / Hyland, R. H. / An, D. / Pang, P. S. / Symonds, W. T. / Mchutchison, J. G. / Stedman, C. A. et al. | 2014
- S4
-
O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPYEsteban, R. / Nyberg, L. / Lalezari, J. / Ni, L. / Doehle, B. / Kanwar, B. / Brainard, D. / Subramanian, M. / Symonds, W. T. / McHutchison, J. G. et al. | 2014
- S5
-
O11 RETREATMENT OF RELAPSERS TO SOFOSBUVIR/RIBAVIRIN WITH SOFOSBUVIR/LEDIPASVIR: COMPLETE AND RAPID VIROLOGIC SUPPRESSION BY WEEK 4Osinusi, A. / Marti, M. / Townsend, K. / Nelson, A. / Kohli, A. / Silk, R. / Pang, P. / Symonds, W. T. / McHutchison, J. / Masur, H. et al. | 2014
- S6
-
O13 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN EUROPEAN PATIENTS WHO RELAPSED AFTER PREVIOUS INTERFERON-BASED THERAPY: THE PROMISE TRIALForns, X. / Lawitz, E. / Zeuzem, S. / Gane, E. J. / Bronowicki, J. P. / Andreone, P. / Horban, A. / Brown, A. S. / Peeters, M. / Lenz, O. et al. | 2014
- S7
-
O15 EFFECTS OF THE FXR AGONIST OBETICHOLIC ACID ON HEPATIC VENOUS PRESSURE GRADIENT (HVPG) IN ALCOHOLIC CIRRHOSIS: A PROOF OF CONCEPT PHASE 2A STUDYMookerjee, R. / Rosselli, M. / Pieri, G. / Beecher-Jones, T. / Hooshmand-Rad, R. / Chouhan, M. / Mehta, G. / Jalan, R. / Shapiro, D. et al. | 2014
- S9
-
O22 TIPS FOR REFRACTORY ASCITES IN CIRRHOSIS: A SINGLE-CENTRE EXPERIENCE USING 8-MM AND 10-MM DIAMETER EXPANDED-POLYTETRAFLUOROETHYLENE (e-PTFE) COVERED STENTLuca, A. / Miraglia, R. / Maruzzelli, L. / Vizzini, G. / Caruso, S. / Tuzzolino, F. et al. | 2014
- S10
-
O24 HEPATOCYTE SPECIFIC KNOCK-OUT OF AUTOPHAGY INDUCES LIVER INJURY, BUT INHIBITS STEATOSIS AND IMPROVES SERUM LIPIDS IN MICE FED A CONTROL AND METHIONINE CHOLINE DEFICIENT DIETKwanten, W. J. / Martinet, W. / De Winter, B. Y. / Van Hoof, V. V. / Bedossa, P. / Michielsen, P. P. / Francque, S. M. et al. | 2014
- S11
-
O27 DOES PNPLA3 INCREASE LIVER FAT BY EXTRA-HEPATIC MECHANISMS?Lallukka, S. / Kotronen, A. / Perttilä, J. / Olkkonen, V. M. / Yki-Järvinen, H. et al. | 2014
- S12
-
O29 ALTERED MITOCHONDRIA IN LIVER-SPECIFIC PROHIBITIN-2 NULL MICE INDUCES HEPATIC DAMAGES ASSOCIATED WITH STEATOSIS AND IMPAIRED GLUCONEOGENESISMartin-Levilain, J. / Supale, S. / Merkwirth, C. / Metzger, D. / Chambon, P. / Langer, T. / Maechler, P. et al. | 2014
- S13
-
O31 GENDER DISPARITY AND REAL-LIFE PRACTICE SETTING DIFFERENCES IN ACTUAL TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B MEETING CRITERIA FOR ANTIVIRAL THERAPYKim, L. H. / Nguyen, V. G. / Trinh, H. N. / Li, J. / Zhang, J. Q. / Nguyen, M. et al. | 2014
- S23
-
O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDYKowdley, K. V. / Stuart, G. C. / Reddy, R. K. / Rossaro, L. / Bernstein, D. E. / An, D. / Svarovskaia, E. S. / Hyland, R. H. / Pang, P. S. / Symonds, W. T. et al. | 2014
- S24
-
O59 MICE WITH AXIN-1 LIVER SPECIFIC DELETION DEVELOP HEPATOCELLULAR CARCINOMAS WITHOUT BETA-CATENIN ACTIVATIONDahmani, R. / Tournier, E. / Coulouarn, C. / Just, P. A. / Terris, B. / Gilgenkrantz, H. / Perret, C. et al. | 2014
- S25
-
O61 EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDYLawitz, E. / Hezode, C. / Gane, E. / Tam, E. / Lagging, M. / Balart, L. / Rossaro, L. / Ghalib, R. / Shaughnessy, M. / Hwang, P. et al. | 2014
- S26
-
O64 EFFECT OF BASELINE NS5A POLYMORPHISMS ON VIROLOGIC RESPONSE TO THE ALL-ORAL COMBINATION OF DACLATASVIR + SOFOSBUVIR ± RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTIONMcPhee, F. / Zhou, N. / Yang, X. / Hernandez, D. / Chiarella, J. / Kozal, M. et al. | 2014
- S29
-
O71 MASSIVE HEPATIC NECROSIS IS A CRITICAL PATHOLOGICAL FEATURE TO DISTINGUISH ACUTE-ON-CHRONIC LIVER FAILURE AS A SEPARATE ENTITY FROM CIRRHOTIC PATIENTS WITH ACUTE DECOMPENSATIONLi, H. / Xia, Q. / Li, S. T. / Yang, S. Y. / Zeng, B. / Wang, T. L. / Weng, H. L. et al. | 2014
- S30
-
O74 URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) IS A STRONG PREDICTOR OF SHORT-TERM OUTCOME IN PATIENTS WITH ACUTE DECOMPENSATION OF CIRRHOSIS. RELATIONSHIP WITH ACUTE-ON-CHRONIC LIVER FAILURE (ACLF)Ariza, X. / Angeli, P. / Barreto, R. / Jalan, R. / Morales Ruiz, M. / Elia, C. / Sola, E. / Garcia, E. / Nevens, F. / Trebicka, J. et al. | 2014
- S31
-
O76 THE OCCURRENCE OF SPONTANEOUS BACTERIAL PERITONITIS CLOSES THE THERAPEUTIC WINDOW OF OPPORTUNITY FOR NON-SELECTIVE BETA BLOCKER TREATMENT IN CIRRHOTIC PATIENTS WITH ASCITESMandorfer, M. / Bota, S. / Schwabl, P. / Bucsics, T. / Pfisterer, N. / Kruzik, M. / Hagmann, M. / Blacky, A. / Ferlitsch, A. / Sieghart, W. et al. | 2014
- S32
-
O79 PROTHROMBOTIC GENETIC RISK FACTORS ARE ASSOCIATED WITH LIVER STIFFNESS IN THE GENERAL POPULATION: RESULTS FROM THE ROTTERDAM STUDYPlompen, E. P. / Darwish Murad, S. / Schouten, J. N. / Hansen, B. E. / Loth, D. W. / Hofman, A. / Uitterlinden, A. G. / Stricker, B. H. / Janssen, H. L. / Leebeek, F. W. et al. | 2014
- S33
-
O82 CLINICAL UTILITY OF NON-INVASIVE MEASURES OF FIBROSIS IN THE AMBULATORY POPULATIONNguyen, T. A. / Deshazo, J. P. / Thacker, L. R. / Sanyal, A. J. et al. | 2014
- S35
-
O86 EUROPEAN RESPONSES IN FOCUS: COMPARING VIRAL HEPATITIS AND HIV RELATED DEATHS IN EUROPE 1990–2010 IN THE GLOBAL BURDEN OF DISEASE STUDY 2010Cowie, B. C. / Allard, N. / MacLachlan, J. H. et al. | 2014
- S36
-
O89 IMPACT OF NEW DAA-CONTAINING REGIMENS ON HCV TRANSMISSION AMONG INJECTING DRUG USERS (IDUS): A MODEL-BASED ANALYSIS (ANRS 12376)Cousien, A. / Tran, V. C. / Jauffret-Roustide, M. / Deuffic-Burban, S. / Dhersin, J. S. / Yazdanpanah, Y. et al. | 2014
- S38
-
O93 GENE EXPRESSION-BASED PROGNOSTIC SIGNATURE AND GENOMIC CHARACTERIZATION OF FIBROLAMELLAR HEPATOCELLULAR CARCINOMACornella, H. / Alsinet, C. / Sayols, S. / Zhang, Z. / Hao, K. / Cabellos, L. / Quaglia, A. / Villanueva, A. / Hoshida, Y. / Nagorney, D. M. et al. | 2014
- S39
-
O96 HEMATOPOIETIC CELLS-DERIVED JNK1 DRIVES HEPATIC INJURY AND HEPATOCELLULAR CARCINOMA IN IKKg/NEMO-DELETED LIVERSCubero, F. J. / Zhao, G. / Nevzorova, Y. A. / Al Masaoudi, M. / Verdier, J. / Peng, J. / Schaefer, F. M. / Hatting, M. / Hermanns, N. / Boekschoten, M. V. et al. | 2014
- S40
-
O99 INFLAMMATORY Wnt DRIVES INTRAHEPATIC CHOLANGIOCARCINOMA GROWTH AND CAN BE THERAPEUTICALLY INHIBITED IN VIVO TO REDUCE TUMOUR BURDENBoulter, L. / Guest, R. V. / Kendall, T. / Walker, R. / Wojtacha, D. / Robson, A. J. / Samuel, K. / Wigmore, S. J. / Sansom, O. J. / Forbes, S. J. et al. | 2014
- S41
-
O102 PROLIFERATION OF HBV-INFECTED HUMAN HEPATOCYTES IN HUMANIZED MICE PROMOTES THE OCCURRENCE OF VIRAL INTEGRATIONS WITHIN THE HOST GENOMEAllweiss, L. / Volz, T. / Giersch, K. / Lohse, A. W. / Petersen, J. / Lütgehetmann, M. / Dandri, M. et al. | 2014
- S42
-
O105 MICE WITH HUMAN LIVERS AS A NEW MODEL OF HEPATITIS E VIRUS INFECTION AND PRECLINICAL DRUG EVALUATIONLutgehetmann, M. / Giersch, K. / Allweiss, L. / Lohse, A. W. / Polywka, S. / Pischke, S. / Petersen, J. / Volz, T. / Dandri, M. et al. | 2014
- S43
-
O108 NATURALLY OCCURRING HBV CORE DELETION MUTANTS ENCODE CORE-POLYMERASE FUSION PROTEINS WHICH BIND TO MICRORNAS PERTURBING THE REGULATORY FUNCTION AND ENHANCING HEPATOMA CELL GROWTHYeh, C. T. / Huang, Y. H. / Tseng, Y. H. / Lin, W. R. / Hung, G. / Chen, T. C. / Lee, W. C. et al. | 2014
- S45
-
O110 AN INTERNATIONAL COLLABORATIVE STUDY ASSESSING THE ROLE OF AETIOLOGY AND STAGE IN SURVIVAL IN HCC – IMPLICATIONS FOR SCREENINGJohnson, P. / Berhane, S. / Satomura, S. / Tada, T. / Kumada, T. / Teng, M. / Skowronska, A. / Cox, T. / Palmer, D. / Yeo, W. et al. | 2014
- S49
-
O118 A MUTATION IN THE HEPATITIS E VIRUS POLYMERASE ASSOCIATED WITH RIBAVIRIN TREATMENT FAILURE HAS A REPLICATION ADVANTAGE IN VITRODebing, Y. / Gisa, A. / Suneetha, P. V. / Bremer, B. / Dallmeier, K. H. / Manns, M. / Pischke, S. / Neyts, J. / Wedemeyer, H. et al. | 2014
- S50
-
O121 SCI-B-VAC IS SUPERIOR TO ENGERIX-B FOR PREVENTING HBV VERTICAL TRANSMISSIONSaed, N. / Hakim, M. / Nijim, Y. / Farah, N. / Jamalia, J. / Nuser, T. / Ismael, K. / Ghantous, R. / Amer, J. / Safadi, R. et al. | 2014
- S52
-
O126 EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-β RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PDGiannelli, G. / Faivre, S. / Santoro, A. / Kelley, R. K. / Merle, P. / Gane, E. / Douillard, J. Y. / Waldschmidt, D. / Mulcahy, M. / Costentin, C. et al. | 2014
- S55
-
O133 NOVEL PROTEIN MARKERS IDENTIFIED IN BILE AND SERUM ARE ASSOCIATED WITH A DIAGNOSIS OF PRIMARY SCLEROSING CHOLANGITIS, DISEASE SEVERITY, AND TRANSPLANT-FREE SURVIVALVesterhus, M. / Holm, A. / Hov, J. R. / Andersen, I. M. / Schrumpf, E. / Paulsen, V. / Bjørnstad, M. / Lundin, K. / Zweers, S. J. / Vatn, M. et al. | 2014
- S56
-
O134 IDENTIFYING APPROACHES TO INTERVENTION IN PRIMARY SCLEROSING CHOLANGITIS (PSC): EFFECTOR FUNCTIONS OF CD28 NEGATIVE T CELLS AND THEIR MODULATION BY VITAMIN DLiaskou, E. / Jeffery, L. E. / Suresh, S. / Trivedi, P. / Reynolds, G. / Bruns, T. / Adams, D. H. / Sansom, D. M. / Hirschfield, G. M. et al. | 2014
- S57
-
O136 A NOVEL, HYBRID RECOMBINANT AAV-piggyBac TRANSPOSON VECTOR PERMITS ROBUST LONG-TERM PHENOTYPE CORRECTION OF THE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TYPE 3 MOUSE MODEL IN VIVOSiew, S. M. / Cunningham, S. C. / Alexander, I. E. et al. | 2014
- S67
-
P3 INVALIDATION OF OSTEOPONTIN AGGRAVATES HEPATIC INJURY INDUCED BY ISCHEMIA–REPERFUSION IN MICEPatouraux, S. / Rousseau, D. / Rubio, A. / Lauron, J. / Bonnafous, S. / Lavallard, V. J. / Saint-Paul, M. C. / Bailly-Maitre, B. / Tran, A. / Crenesse, D. et al. | 2014
- S69
-
P10 INTERFERON LAMBDA 4 (IFNL4) POLYMORPHISM PREDICTS RESPONSE TO HEPATITIS C TREATMENT AFTER LIVER TRANSPLANTATIONFernández-Carrillo, C. / González, P. / Crespo, G. / Coto-Llerena, M. / Navasa, M. / Forns, X. / Pérez-del-Pulgar, S. et al. | 2014
- S70
-
P13 HUMAN INTRAHEPATIC CD4CD25FOXP3 REGULATORY T CELLS TREATED BY RAPAMYCIN AND RETINOIC ACID EFFECTIVELY SUPPRESS ALLOGENIC T EFFECTORS OF PERIPHERAL BLOODSharma, R. / Jabri, Y. / Xystrakis, E. / Srinivasan, P. / Prachalias, A. / Huang, X. / Vijay, G. M. / Heaton, N. / Ma, Y. / Jassem, W. et al. | 2014
- S71
-
P16 ‘IN VIVO’ MAGNETIC RESONANCE SPECTROSCOPY WITH HYPERPOLARIZED PYRUVATE EARLY DETECTS LACTATE FORMATION IN ALF RATSChavarria, L. / Romero-Giménez, J. / Monteagudo, E. / Lope-Piedrafita, S. / Genesca, J. / Cordoba, J. et al. | 2014
- S73
-
P22 NUMERICAL SIMULATIONS TO CHARACTERIZE THE HEPATIC MICROCIRCULATION IN HUMAN CIRRHOSISPeeters, G. / Debbaut, C. / Cornillie, P. / Dierick, M. / Monbaliu, D. / Segers, P. et al. | 2014
- S74
-
P24 L-ORNITHINE PHENYLACETATE REDUCES AMMONIA IN PIGS WITH ACUTE LIVER FAILURE THROUGH PHENYLACETYLGLYCINE FORMATION: A NOVEL AMMONIA-LOWERING PATHWAYKristiansen, R. G. / Rose, C. / Fuskevåg, O. M. / Mæhre, H. / Revhaug, A. / Jalan, R. / Ytrebø, L. M. et al. | 2014
- S75
-
P28 EVIDENCE FOR INTRACELLULAR IMMUNOMODULATORY AND ANTIOXIDANT ACTION OF ALBUMIN TO PROVIDE ENDOTHELIAL PROTECTION IN LIVER FAILUREGarcia Martinez, R. / Andreola, F. / Mehta, G. / Poulter, K. / Oria, M. / Chiara, F. / Jalan, R. et al. | 2014
- S80
-
P42 PPARg AGONIST PIOGLITAZONE REDUCES PORTOSYSTEMIC COLLATERAL BLOOD FLOW VIA MODULATION OF ANGIOGENESIS AND INFLAMMATION IN PPVL RATSSchwabl, P. / Payer, B. A. / Grahovac, J. / Boucher, Y. / Klein, S. / Trebicka, J. / Angermayer, B. / Trauner, M. / Peck-Radosavljevic, M. / Reiberger, T. et al. | 2014
- S83
-
P51 DESUMOYLATION OF HYPOXIA INDUCIBLE FACTOR (HIF)-2a BY SENP1 IS INVOLVED IN HPPCn-ENHANCED SORAFENIB RESISTANCE UNDER HYPOXIA IN HEPATOCELLULAR CARCINOMAZhu, B. / Lin, S. S. / Liu, P. F. / Li, Y. F. / Gao, H. Y. / Su, Z. Y. / Sun, H. Y. / Wang, L. S. / Cui, C. P. et al. | 2014
- S84
-
P54 TEMPORAL DYNAMICS AND THERAPEUTIC POTENTIAL OF THE UNFOLDED PROTEIN RESPONSE IN HEPATOCELLULAR CARCINOMAVandewynckel, Y. P. / Laukens, D. / Geerts, A. / Bogaerts, E. / Paridaens, A. / Verhelst, X. / Van Steenkiste, C. / Descamps, B. / Vanhove, C. / Libbrecht, L. et al. | 2014
- S85
-
P57 SIGNIFICANCE OF SERUM miR-10b-3p IN PREDICTING PRESENCE OF MICROVASCULAR INVASION OF HEPATOCELLULAR CARCINOMA (HCC)Yoon, E. L. / Yeon, J. E. / Ko, E. / Je, J. H. / Yoo, Y. J. / Kang, K. / Kang, S. H. / Kim, H. R. / Lee, H. J. / Suh, S. J. et al. | 2014
- S86
-
P60 HUMAN HEPATOCELLULAR CARCINOMA DENDRITIC CELL INTERACTIONS INDUCE A NOVEL SUBSET OF CD8+REGULATORY T-CELLS WHICH MEDIATE IMMUNOSUPPRESSION THROUGH CD39Li, K. K. / Resheq, Y. J. / Curbishley, S. M. / Ward, S. T. / Bruns, T. / Zimmermann, H. W. / Trivedi, P. J. / Weston, C. J. / Adams, D. H. et al. | 2014
- S87
-
P63 SMAD4-DEPENDENT REGULATION OF HEPATOCELLULAR CARCINOMA GROWTH AND PROGRESSIONHernanda, P. Y. / Kan, C. / Das, A. M. / Sideras, K. / Bots, S. J. / Janssen, H. L. / Kodach, L. L. / Metselaar, H. J. / Kwekkeboom, J. / Sprengers, D. et al. | 2014
- S89
-
P70 STEM CELL NICHE AND MACROPHAGES IN HUMAN CHOLANGIOCARCINOMARaggi, C. / Correnti, M. / Invernizzi, P. et al. | 2014
- S90
-
P73 A TRANSFORMING GROWTH FACTOR KINASE I INHIBITOR, LY2157299, MODULATES STEMNESS-RELATED BIOMARKERS IN HCCRani, B. / Di Turi, F. / Lupo, L. / Cao, Y. / Malfettone, A. / Fabregat, I. / Villa, E. / Giannelli, G. et al. | 2014
- S93
-
P82 TGF-β SIGNALING REGULATOR EXPRESSION IN HUMAN HCC: RESULTS FROM MICROARRAY DATA META ANALYSESDediulia, T. / Dropmann, A. / Itzel, T. / Meindl-Beinker, N. / Teufel, A. / Coulouarn, C. / Dooley, S. et al. | 2014
- S94
-
P85 CHOLANGIOCARCINOMA (CCA) EXPRESS CHEMOKINE RECEPTOR CXCR7: IMPORTANT ROLE OF CXCR7 IN MEDIATING CXCL12 INDUCED CCA CELLS CHEMOTAXIS AND SURVIVALGentilini, A. / Roumbouts, K. / Pinzani, M. / Caligiuri, A. / Raggi, C. / Invernizzi, P. / Raschioni, C. / Marra, F. et al. | 2014
- S95
-
P88 USAGE OF ADAPTER-MEDIATED RETARGETING OF ONCOLYTIC ADENOVIRUSES FACILITATES ANTIGEN-SPECIFIC CD8 T CELL RESPONSES AND LEADS TO REDUCED HEPATOTOXICITY IN MICEUreche, C. I. et al. | 2014
- S96
-
P91 EFFECT OF TOLL-LIKE RECEPTOR 7 AND 9 TARGETED THERAPY TO PREVENT THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMAMohamed, F. / Al-Jehani, R. / Minogue, S. / Andreola, F. / Winstanley, A. / Olde Damink, S. / Malagó, M. / Davies, N. / Loung, T. V. / Dhillon, A. et al. | 2014
- S97
-
P94 c-Rel AND p27Kip ARE DOWNSTREAM TARGETS OF ERK5 IN HEPATOCELLULAR CARCINOMA (HCC) IN VIVO AND IN VITRODi Maira, G. / Rovida, E. / Navari, N. / Cannito, S. / Sbarba, P. D. / Parola, M. / Marra, F. et al. | 2014
- S98
-
P97 NEW INSIGHTS IN HOXA13 AND HOTTIP ROLE AS PROGNOSTIC FACTORS IN HEPATOCELLULAR CARCINOMAQuagliata, L. / Matter, M. / Piscuglio, S. / Tornillo, L. / Heim, M. / Cillo, C. / Terracciano, L. et al. | 2014
- S99
-
P100 Nur77 MEDIATES BILE ACID-INDUCED DEATH AND SURVIVAL IN LIVER AND COLON CELLSHu, Y. / Chau, T. / Liu, H. X. / Wan, Y. J. et al. | 2014
- S100
-
P103 SUCCESSFUL CRYOPRESERVATION OF HUMAN BILIARY TREE STEM/PROGENITOR CELLS (hbTSCS) ISOLATED FROM ADULT LIVER BASED ON GOOD MANUFACTURING PRACTICECardinale, V. / Gentile, R. / Nevi, L. / Fraveto, A. / Carpino, G. / Torrice, A. / Pasqualino, V. / Melandro, F. / Mennini, G. / Nudo, F. et al. | 2014
- S101
-
P106 ADULT HUMAN BILIARY TREE STEM/PROGENITOR CELLS (hbTSCS) ARE EFFICIENTLY REPROGRAMMED TO FUNCTIONAL INSULIN-SECRETING β-PANCREATIC ISLET CELLS BY A NEWLY SYNTHESIZED HUMAN Pdx1 PEPTIDECardinale, V. / Scafetta, G. / Puca, R. / De Canio, M. / Sicilia, F. / Carpino, G. / Casa, D. / Federici, G. / Berloco, P. B. / Gaudio, E. et al. | 2014
- S102
-
P109 CANALS OF HERING ARE REMNANTS OF DISTAL BILE DUCTS AFTER REGENERATION OF HEPATOCYTES: A STUDY OF EARLY CHRONIC LIVER DISEASE IN HUMANSStueck, A. E. / Wanless, I. R. et al. | 2014
- S103
-
P112 LIVER DAMAGE DETERMINES THE GENE EXPRESSION PROFILE OF LIVER PROGENITOR CELLS AND THEIR CONTRIBUTION TO HEPATIC REGENERATIONRodrigo-Torres, D. / Affò, S. / Coll, M. / Morales-Ibanez, O. / Millán, C. / Blaya, D. / Lozano, J. J. / Caballería, J. / Arroyo, V. / Ginès, P. et al. | 2014
- S107
-
P126 INCREASED FREQUENCY OF CD8 T CELL RESPONSES TO T CELL APOPTOSIS-DERIVED ANTIGENS IN CHRONICALLY-HCV INFECTED INDIVIDUALS NON-RESPONDING TO PEG-IFNa/RIBAVIRINMartini, H. / Citro, A. / Martire, C. / Accapezzato, D. / Cavallari, E. N. / Labbadia, G. / DEttorre, G. / Vullo, V. / Barnaba, V. et al. | 2014
- S108
-
P129 HEPATITIS C VIRUS MEK1- AND TC-PTP-DEPENDENTLY CONVERTS EPIDERMAL GROWTH FACTOR (EGF) INTO A POTENT INDUCTOR OF CXCR2 LIGAND EXPRESSIONGröpper, C. / Triller, N. / Eisenbürger, S. / Bartenschlager, R. / Häussinger, D. / Bode, J. G. et al. | 2014
- S110
-
P135 DEPLETION OF H2O2 BY CATALASE INDUCES MYELOID-DERIVED SUPPRESSOR CELLS – A NOVEL MECHANISM OF IMMUNE-REGULATION BY HEPATIC STELLATE CELLSResheq, Y. J. / Li, K. K. / Wards, S. / Wilhelm, A. / Garg, A. / Curbishley, S. M. / Zimmermann, H. W. / Jitschin, R. / Mougiakakos, D. / Weston, C. et al. | 2014
- S111
-
P138 SERONEGATIVE ACUTE LIVER FAILURE REPRESENTS A MACROPHAGE–T CELL ACTIVATION SYNDROMETriantafyllou, E. / Pop, O. T. / Abeles, R. D. / Khamri, W. / Possamai, L. / Hussain, M. / Bernal, W. / Auzinger, G. / Heneghan, M. A. / Heaton, N. et al. | 2014
- S112
-
P140 MODELLING THE LIVER IMMUNE MICROENVIRONMENT: FACTORS THAT DEFINE ANTIVIRAL ACTIVITY OF T CELLSLawrence, T. M. / Peng, Y. C. / Wilson, G. K. / Zhang, Y. / Thimme, R. / Dong, T. / McKeating, J. A. et al. | 2014
- S113
-
P144 TREM1-DEFICIENCY ACCELERATES VIRAL CLEARANCE IN A MOUSE MODEL OF LCMV-INDUCED ACUTE VIRAL HEPATITISKozik, J. H. / Trautmann, T. / Carambia, A. / Eissing, L. / Lohse, A. W. / Wiegard, C. / Heeren, J. / Herkel, J. et al. | 2014
- S114
-
P147 CD4+ T CELL EGRESS THROUGH HEPATIC EPITHELIA HAS PROFOUND IMPLICATIONS FOR PHENOTYPE AND FUNCTIONNiesen, D. / Liaskou, E. / Jeffery, L. / Purswani, S. / Bruns, T. / Adams, D. H. / McKeating, J. A. / Thimme, R. / Starnataki, Z. et al. | 2014
- S118
-
P159 CO-INHIBITORY RECEPTOR LAG-3 POSITIVE CD8 T CELLS PRODUCE IMMUNOSUPPRESSIVE TGF-β IN CHRONIC HBVLubowiecki, M. / Pallmer, K. / Jajbhay, D. / Pallett, L. J. / Gill, U. / Kennedy, P. T. / Maini, M. / Schurich, A. et al. | 2014
- S119
-
P162 TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL TARGETING OF FVIII EXPRESSION TO OVERCOME IMMUNOLOGICAL RESPONSES TO GENE THERAPY FOR HEMOPHILIA AMerlin, S. / Cannizzo, E. S. / Bruscaggin, V. / Feola, M. / Follenzi, A. et al. | 2014
- S120
-
P164 MONOCYTE EXHAUSTION: A MECHANISTIC EXPLANATION FOR SUSCEPTIBILITY TO INFECTION IN LIVER FAILUREBernsmeier, C. / Patel, V. / Tidswell, R. / Triantafyllou, E. / Singanayagam, A. / Khamri, W. / Agarwal, K. / Heneghan, M. / Willars, C. / Bernal, W. et al. | 2014
- S121
-
P166 A COACH, A PLAYMAKER, A DEFENDER AND STRIKERS: AN EPIGENETIC-TARGET INTERPLAY IN HCV/HCCFouad, M. M. / Elemam, N. M. / Sherif, H. B. / El Sobky, S. A. / Yacoub, R. A. / Abelhamid, A. K. / Elbaz, T. / Mohey El Din, M. A. / Fawzy, I. O. / El Tayebi, H. M. et al. | 2014
- S122
-
P169 INTERFERON INDUCIBLE SECRETED FACTORS RESTRICT HBV BINDINGXia, Y. / Blossey, C. / Esser, K. / Lucifora, J. / Protzer, U. et al. | 2014
- S123
-
P172 COMPARISON OF DIFFERENT IMMUNOREGULATORY PATHWAYS IN HEPATITIS B VIRUS-SPECIFIC CD8+ T-CELL FAILUREBusch, K. / Hoh, A. / Thimme, R. et al. | 2014
- S127
-
P185 PROTEIN KINASE C-INDUCED ENDOCYTOSIS OF SODIUM TAUROCHOLATE COTRANSPORTING POLYPEPTIDE MEDIATES CELLULAR ENTRY OF HEPATITIS B VIRUS IN AN IN VITRO HBV MODELChung, J. W. / Moon, I. Y. / Yang, S. W. / Jang, E. S. / Jeong, S. H. / Kim, J. W. et al. | 2014
- S128
-
P188 A HIGH-THROUGHPUT HDV INFECTION MODEL SYSTEM FOR SCREENING OF ANTIVIRALS AND HOST-TARGETING COMPOUNDSVerrier, E. R. / Tawar, R. G. / Schuster, C. / Brino, L. / Bach, C. / Heydmann, L. / Habersetzer, F. / Doffoel, M. / Mckeating, J. / Sureau, C. et al. | 2014
- S129
-
P191 HEPATITIS B AND C VIRUS PROMOTE CROSSTALK BETWEEN HYPOXIA AND GLUCOCORTICOID SIGNALLING PATHWAYS TO RE-PROGRAMME HEPATOCYTE METABOLISM AND TO EVADE HOST INTERFERONSWilson, G. K. / Meredith, L. W. / Greenland, D. / Mailly, L. / Tennant, D. / Ashcroft, M. / Baumert, T. F. / Tomlinson, J. W. / Hubscher, S. G. / Eeden, F. V. et al. | 2014
- S130
-
P194 THE RISK OF HEPATITIS B-RELATED HEPATOCELLULAR CARCINOMA (HCC) IS REDUCED WITH ANTIVIRAL THERAPY: EVIDENCE FROM 3 HCC PREDICTION MODELSAbu-Amara, M. / Cerecchi, O. / Mahli, G. / Sharma, S. / Yim, C. / Shah, H. / Wong, D. K. / Janssen, H. L. / Feld, J. J. et al. | 2014
- S133
-
P203 THE NEWLY AVAILABLE SEQUENCE-BASED GENOTYPING ASSAYS ARE MORE ACCURATE FOR HEPATITIS C VIRUS (HCV) GENOTYPING THAN PREVIOUS LINE-PROBE ASSAYSMacartney, M. J. / Abdi-Ashir, I. / McCormick, A. L. / Labbett, W. / Irish, D. / Webster, D. P. / Haque, T. et al. | 2014
- S134
-
P206 HEPATITIS C VIRUS COMPARTMENTALISATION: UNRAVELLING GENETIC COMPLEXITY WITHIN THE LIVERHedegaard, D. L. / Tully, D. C. / Reynolds, G. M. / Rowe, I. / Hübscher, S. G. / Power, K. / Tarr, A. W. / Ball, J. / Allen, T. / McKeating, J. A. et al. | 2014
- S135
-
P209 INCREASED DNA METHYLATION IS OBSERVED IN HCV rs12979860 CC HCV PATIENTS WITH LOW HEPATOCELLULAR MxA PROTEIN LEVELSMessineo, A. / DeBoer, B. / Platten, M. / Huang, Y. / Jeffrey, G. / MacQuillan, G. et al. | 2014
- S139
-
P221 VIROLOGY ANALYSES OF SIMEPREVIR IN PHASE 2B AND 3 STUDIESLenz, O. / Verbinnen, T. / Fevery, B. / Tambuyzer, L. / Vijgen, L. / Peeters, M. / Buelens, A. / Beumont-Mauviel, M. / Picchio, G. / de Meyer, S. et al. | 2014
- S140
-
P224 DIFFERENT PROFILE OF NATURAL RESISTANCE TO NS3 PROTEASE INHIBITORS IN HEPATITIS C SUBTYPES 1A AND 1CBagaglio, S. / Messina, E. / Smacchia, A. / Torre, L. D. / Galli, A. / Merli, M. / Hasson, H. / Lazzarin, A. / Uberti-Foppa, C. / Morsica, G. et al. | 2014
- S142
-
P231 HEPATITIS C VIRUS POTENTLY ACTIVATES HUMAN CD161/MAIT (MUCOSAL ASSOCIATED INVARIANT T) CELLSThompson, F. M. / van Wilgenburg, B. / Ramamurthy, N. / Willberg, C. / Oo, Y. H. / Fabris, P. / Klenerman, P. et al. | 2014
- S143
-
P234 MYELOID-DERIVED SUPPRESSOR CELLS AND DENDRITIC CELLS FOR IMPAIRED RESPONSE TO VACCINE IN MICE WITH NONALCOHOLIC FATTY LIVER DISEASEAkbar, S. M. / Chen, S. / Al-Mahtab, M. / Miyake, T. / Hiasa, Y. et al. | 2014
- S144
-
P237 HEPATIC INFLAMMATION INCREASES IN CD36 DEFICIENT MICE FED WITH A HIGH-FAT DIETSheedfar, F. / Oosterveer, M. / Moesker, B. / Kloosterhuis, N. / Runow, K. / de Bruin, A. / Hofker, M. / Koonen, D. et al. | 2014
- S145
-
P240 BILBERRY EXTRACT ATTENUATES DEVELOPMENT OF NONALCOHOLIC STEATOHEPATITIS IN ApoE3L MICEMorrison, M. C. / Liang, W. / Salic, K. / Mulder, P. / Wielinga, P. / Kooistra, T. / Heeringa, P. / Kleemann, R. et al. | 2014
- S147
-
P247 SIMVASTATIN ATTENUATES FIBROSIS IN A NEW RODENT NASH MODEL WITHIN THE METABOLIC SYNDROMESchierwagen, R. / Maybüchen, L. / Klein, S. / Hiththejeti, K. / Lütjohann, D. / Plat, J. / Strassburg, C. P. / Nickenig, G. / Sauerbruch, T. / Zimmer, S. et al. | 2014
- S148
-
P250 BENEFICIAL EFFECTS ON WEIGHT GAIN, HEPATIC STEATOSIS AND EXPRESSION OF LIPOGENIC TARGET GENES IN A MURINE OBESITY MODEL AFTER IL-1 TYPE CYTOKINE INACTIVATIONWohlfahrt, J. / Fettelschoss, A. / Kündig, T. / Hermanns, H. / Müllhaupt, B. / Schmitt, J. / Geier, A. et al. | 2014
- S149
-
P253 ENDOPLASMIC RETICULUM STRESS DOES NOT CONTRIBUTE TO NASH PATHOGENESIS IN OBESE, DIABETIC MICE WITH METABOLIC SYNDROMELegry, V. / Van Rooyen, D. M. / Lambert, B. A. / Sempoux, C. / Poekes, L. / Español-Suñer, R. / Horsmans, Y. / Farrell, G. C. / Leclercq, I. A. et al. | 2014
- S150
-
P257 THE ROLE OF THE ADAPTIVE IMMUNE SYSTEM IN THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE IN MORBIDLY OBESE PATIENTSIruzubieta, P. / Loste, M. T. / Puente, A. / Cabezas, J. / Segundo, D. S. / Azueta, A. / Cruz, C. S. / Estebanez, A. / Useros, A. L. / Domínguez, A. et al. | 2014
- S151
-
P260 EFFECTS OF ADENOSINE A2A AND A1 RECEPTORS STIMULATION ON PALMITIC ACID AND HYPOXIA REOXYGENATION INJURY OF STEATOTIC MICE HEPATOCYTESImarisio, C. / Revanna, C. B. / Alchera, E. / Carini, R. et al. | 2014
- S152
-
P263 STEATOSIS-INDEPENDENT PREVENTION OF LIVER FIBROSIS VIA THE TRANSREPRESSIVE ACTIVITY OF PPARaPawlak, M. / Baugé, E. / Bourguet, W. / De Bosscher, K. / Lalloyer, F. / Tailleux, A. / Lebherz, C. / Lefebvre, P. / Staels, B. et al. | 2014
- S153
-
P266 STUDY ON CHANGES OF FFA AND SERUM LIPIDS IN PREECLAMPSIA-LIKE MOUSE MODELS GENERATED BY DIFFERENT MEANSYang, Z. / Han, Y. / Ding, X. et al. | 2014
- S155
-
P273 THE PATHOLOGICAL PROGRESSION OF NON-ALCOHOLIC FATTY LIVER DISEASE CORRELATES WITH GUT MICROBIOTA COMPOSITION IN MICE: FROM NON-ALCOHOLIC FATTY LIVER TO NON-ALCOHOLIC STEATOHEPATITISPeng, J. / Huang, F. / Li, X. / Chen, L. / Feng, Q. / Hu, Y. et al. | 2014
- S157
-
P276 TLR9 MEDIATES ADIPOSE AND LIVER INFLAMMATION IN METABOLICALLY OBESE MURINE MODELS OF NON-ALCOHOLIC STEATOHEPATITISHaczeyni, F. / Mridha, A. / Yeh, M. / Teoh, N. / Farrell, G. et al. | 2014
- S162
-
P292 ROLE OF NECROPTOSIS IN PATIENTS WITH LIVER DISEASE AND IN RAT LIVER CELL INJURYAfonso, M. B. / Ferreira, D. M. / Cortez-Pinto, H. / Castro, R. E. / Rodrigues, C. M. et al. | 2014
- S163
-
P295 EXPRESSION OF FATTY ACID BINDING PROTEINS (FABPS) IN A MOUSE MODEL OF OBESITY-DEPENDENT HEPATOCELLULAR CARCINOMA (HCC)Thompson, K. J. / Nazari, S. S. / Sindram, D. / McKillop, I. H. et al. | 2014
- S164
-
P298 ACETAMINOPHEN (APAP) FORMULATIONS CONTAINING METHYL-SULFONYL-METHANE AND ISOSILYBIN B AMELIORATE APAP-MEDIATED LIVER TOXICITY WHILE RETAINING APAP EFFICACYYaacov, A. B. / Lichtenstein, Y. / Shabat, Y. / Sobol, T. / Mograbi, Y. / Ilan, Y. et al. | 2014
- S165
-
P300 ALCOHOLIC LIVER DISEASE IN DENMARK 2006–2011: A POPULATION-BASED DESCRIPTIVE STUDYDeleuran, T. / Vilstrup, H. / Becker, U. / Jepsen, P. et al. | 2014
- S166
-
P303 ALCOHOL DRINKING FREQUENCY AND RISK OF ALCOHOLIC CIRRHOSIS IN MIDDLE-AGED WOMEN AND MEN: RESULTS FROM A POPULATION-BASED COHORT STUDYAskgaard, G. / Tolstrup, J. S. et al. | 2014
- S170
-
P313 AMIODARONE HEPATOTOXICITY IS MEDIATED VIA INDUCTION OF STEATOSIS, ER STRESS AND mTOR ACTIVATION IN-VIVO AND IN-VITROErez, N. / Cohen, R. / Uzi, D. / Scaiewicz, V. / Meuller, T. / Tirosh, B. / Shibolet, O. et al. | 2014
- S173
-
P322 ALCOHOLIC LIVER DISEASE ALTERS GLYCOSYLATION-ASSOCIATED GENE EXPRESSIONLee, A. / dAvigdor, W. M. / Christiansen, M. N. / Harrison, M. J. / Packer, N. H. / McLennan, S. V. / Shackel, N. A. et al. | 2014
- S174
-
P325 BACLOFENE LEADS TO ALCOHOL CONSUMPTION REDUCTION AND HEPATIC IMPROVEMENT IN CIRRHOTIC PATIENTSBarrault, C. / Lison, H. / Roudot-Thoraval, F. / Sarlon, E. / Béhar, V. / Medmoun, M. / Rosa Hezode, I. / Belloula, D. / Garioud, A. / Hagege, H. et al. | 2014
- S175
-
P328 ROLE OF MYCOPHENOLATE MOFETIL (MMF) IN STEROID NON RESPONSIVE SEVERE ACUTE ALCOHOLIC HEPATITIS: A RANDOMIZED OPEN LABEL PLACEBO CONTROL PROSPECTIVE CLINICAL PILOT TRIAL – MASH TRIALBasu, P. P. / Aloysius, M. / Shah, N. J. / Brown, R. S. et al. | 2014
- S176
-
P331 HUMAN HEPATIC HepaRG CELLS MAINTAIN HIGH INTRINSIC CYP450 ACTIVITY/METABOLISM AND SIGNIFICANTLY OUTPERFORM STANDARD HepG2/C3A CELLS USED IN DRUG PHARMACOLOGY APPLICATIONSNelson, L. J. / Treskes, P. / Henderson, C. J. / Homer, N. / Morgan, K. / LeBled, C. / Grant, M. H. / Plevris, J. N. et al. | 2014
- S177
-
P333 HUMAN HEPATIC HepaRG CO-CULTURE MODEL AS A SENSITIVE AND NON-INVASIVE TOXICOLOGICAL PLATFORM USING ECIS (ELECTRICAL CELL-SUBSTRATE IMPEDANCE SENSING) BIOSENSORSGamal, W. / Treskes, P. / Chesne, C. / Plevris, J. N. / Bagnaninchi, P. O. / Nelson, L. J. et al. | 2014
- S178
-
P335 DYSFUNCTIONAL GUT MICROBIOTA IN ILEO-COLONIC MUCOSA AND STOOL IN ALCOHOLIC CIRRHOSIS IS ASSOCIATED WITH ENDOTOXEMIA: IMPLICATIONS FOR BACTERIAL TRANSLOCATIONBajaj, J. S. / Heuman, D. / Hylemon, P. / Sikaroodi, M. / Ridlon, J. / Pandak, W. M. / Schubert, M. / Fuchs, M. / White, M. / Daita, K. et al. | 2014
- S180
-
P341 NON-INVASIVE IMAGING OF KUPFFER CELL STATUS USING RADIOLABELLED MANNOSYLATED ALBUMINMahajan, V. / Hartimath, S. / Comley, R. / Stefan-Gueldner, M. / Roth, A. / Poelstra, K. / Reker-Smit, C. / Kamps, J. / Dierckx, R. / de Vries, E. et al. | 2014
- S181
-
P344 TRANSLATIONAL STUDY IDENTIFIES NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AS A POTENTIAL MEDIATOR OF LIVER INJURY AND FIBROGENESIS IN ALCOHOLIC HEPATITISOdena, G. / Morales-Ibanez, O. / Affo, S. / Furuya, S. / Rusyn, I. / Altamirano, J. / Sancho-Bru, P. / Arroyo, V. / Gines, P. / Caballeria, J. et al. | 2014
- S182
-
P347 INCIDENCE AND RISK FACTORS FOR EXTRA-HEPATIC MALIGNANCIES (EM) IN PRIMARY BILIARY CIRRHOSIS: A COMPARATIVE STUDY FROM TWO EUROPEAN REFERRAL CENTERSCazzagon, N. / Parès, A. / Spinazzè, A. / Caballeria, L. / Reig, A. / Franceschet, I. / Baldo, V. / Buja, A. / Furlan, P. / Floreani, A. et al. | 2014
- S183
-
P350 PREGNANCY AND PRIMARY BILIARY CIRRHOSIS: A CASE–CONTROL STUDYFranceschet, I. / Infantolino, C. / Magne Tene, I. / Cazzagon, N. / Buja, A. / Gervasi, M. T. / Baldo, V. / Floreani, A. et al. | 2014
- S185
-
P355 GENE EXPRESSION ANALYSIS IDENTIFIES IMMUNE SIGNALING AND COMPLEMENT PATHWAYS IN IgG4-RELATED DISEASECulver, E. L. / Marchi, E. / Manganis, C. / Smit, W. / Makuch, M. / Ramamurthy, N. / Rispens, T. / Klenerman, P. / Barnes, E. et al. | 2014
- S186
-
P358 EFFECT OF TAUROURSODEOXYCHOLIC ACID ON ER STRESS IN CHOLESTATIC LIVER DISEASEParidaens, A. / Bogaerts, E. / Vandewynckel, Y. P. / Van Vlierberghe, H. / Geerts, A. / Colle, I. et al. | 2014
- S187
-
P362 THE BILE ACID RECEPTOR TGR5 CONTROLS BILE ACID POOL HYDROPHOBICITY THROUGH REGULATION OF GALLBLADDER MOTOR FUNCTIONPéan, N. / Doignon, I. / Boisgard, R. / Garcin, I. / Julien, B. / Humbert, L. / Schoonjans, K. / Rainteau, D. / Tordjmann, T. et al. | 2014
- S188
-
P364 CHARACTERIZATION AND OUTCOME OF ANTIMITOCHONDRIAL TYPE 2-POSITIVE PATIENTS WITHOUT A DIAGNOSIS OF PRIMARY BILIARY CIRRHOSIS: A FRENCH NATIONWIDE PROSPECTIVE STUDYDahlqvist, G. / Gaouar, F. / Carrat, F. / Chazouillères, O. / Poupon, R. / Johanet, C. / Corpechot, C. et al. | 2014
- S189
-
P367 PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF USTEKINUMAB IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS WHO HAD AN INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACIDHirschfield, G. M. / Gershwin, M. E. / Strauss, R. / Mayo, M. J. / Levy, C. / Zou, B. / Selmi, C. / Marschall, H. U. / Lindor, K. et al. | 2014
- S192
-
P374 LONG-TERM TREATMENT OF PRIMARY BILIARY CIRRHOSIS WITH THE FXR AGONIST OBETICHOLIC ACID SHOWS DURABLE EFFICACYKowdley, K. / Hirschfield, G. / Chapman, R. / Vincent, C. / Jones, D. / Pares, A. / Luketic, V. / Gordon, S. / Pencek, R. / Marmon, T. et al. | 2014
- S193
-
P377 THE FXR AGONIST OBETICHOLIC ACID IMPROVES A TRANSPLANT-FREE SURVIVAL-PROVEN BIOCHEMICAL RESPONSE CRITERION IN PLACEBO CONTROLLED PRIMARY BILIARY CIRRHOSIS STUDIESLuketic, V. / Gordon, S. G. / Vincent, C. / Chapman, R. / Mayo, M. / Kowdley, K. / Hirschfield, G. / Mason, A. / Lindor, K. / Macconell, L. et al. | 2014
- S194
-
P380 EXPRESSION OF THE FIBROBLAST GROWTH FACTOR 19 (FGF19) IN THE LIVER CORRELATES WITH CLINICAL AND LABORATORY MEASURES IN PATIENTS WITH PRIMARY BILIARY CIRRHOSISWunsch, E. / Milkiewicz, M. / Kempińska-Podhorodecka, A. / Raszeja-Wyszomirska, J. / Trottier, J. / Barbier, O. / Milkiewicz, P. et al. | 2014
- S196
-
P386 Th17 EFFECTOR CELLS MAY BE INVOLVED IN THE BILE DUCT DAMAGE CHARACTERISTIC OF AUTOIMMUNE SCLEROSING CHOLANGITISLiberal, R. / Grant, C. R. / Ma, Y. / Heneghan, M. A. / Mieli-Vergani, G. / Vergani, D. / Longhi, M. S. et al. | 2014
- S197
-
P389 PROTECTIVE ROLE OF MEMBRANE BILE ACID RECEPTOR TGR5 (GPBAR1) IN DDC-INDUCED SCLEROSING CHOLANGITIS IN MICEBaghdasaryan, A. / Jha, P. / Müller, M. / Agostinelli, L. / Saccomanno, S. / Auer, N. / Deutschmann, A. / Zöhrer, C. / Auwerx, J. / Marzioni, M. et al. | 2014
- S198
-
P391 CD2-SPECIFIC OVEREXPRESSION OF CREM ALPHA AGGRAVATES ACUTE CONCANAVALIN A-INDUCED HEPATITISHammerich, L. / Schönherr, C. / Stefkova, M. / Ohl, K. / Luedde, T. / Trautwein, C. / Tenbrock, K. / Tacke, F. et al. | 2014
- S200
-
P398 AUTOIMMUNE HEPATITIS IS A TH1-DRIVEN DISEASEBovensiepen, C. / Sebode, M. / Lohse, A. W. / Schramm, C. / Herkel, J. / Weiler-Normann, C. et al. | 2014
- S201
-
P401 DISEASE PROGRESSION IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS UNDER LONG-TERM TREATMENT WITH URSODEOXYCHOLIC ACID – A HISTOLOGY-BASED ANALYSISSinakos, E. / Vasiliadis, T. / Goulis, I. / Papalavrentios, L. / Perlepe, N. / Patsiaoura, K. / Hytiroglou, P. / Akriviadis, E. et al. | 2014
- S202
-
P404 IDENTIFICATION OF NEW BIOMARKERS IN HEPATITIS B RELATED HEPATOCELLULAR CARCINOMA PATIENTS USING THE MASS SPECTROMETRY AND WESTERN BLOT ANALYSISLee, J. H. / Shim, J. H. / Song, G. W. / Jun, M. J. / Lim, Y. S. / Choi, S. W. / Suh, D. J. et al. | 2014
- S203
-
P407 HBeAg INDEX AND HBVDNA REDUCTION CAN PREDICT LONG TERM RESPONSE OF CHRONIC HEPATITIS B, HBeAg POSITIVE PATIENTS TREATED WITH PEGINTERFERON ALPHA-2a: A THREE-YEAR FOLLOW-UPPhisalprapa, P. / Charatcharoenwitthaya, P. / Chainuwatti, S. / Chotiyaputta, W. / Nimanong, S. / Tanwandee, T. et al. | 2014
- S205
-
P413 ROLE OF KINASES EGFR AND SRC IN ESTRADIOL 17β-GLUCURONIDE (E17G) INDUCED CHOLESTASIS IN ISOLATED RAT HEPATOCYTES COUPLETS (IRHC)Barosso, I. R. / Zucchetti, A. E. / Miszczuk, G. S. / Roma, M. G. / Crocenzi, F. A. / Sánchez Pozzi, E. J. et al. | 2014
- S206
-
P415 PREVENTION OF CHEMOTHERAPY-INDUCED HBV-RELATED HEPATITIS FLARE IN LYMPHOMA PATIENTS WITH RESOLVED HBV INFECTION: COST ANALYSISTsou, H. H. / Yang, H. C. / Chuang, M. H. / Wu, H. Y. / Hsu, Y. T. / Chang, W. J. / Hsiao, C. F. / Hsu, C. et al. | 2014
- S207
-
P419 HGF SIGNALING PATHWAY AND CELL POLYPLOIDIZATION IN CHOLESTATIC LIVERKiparoidze, S. / Dzidziguri, D. / Bakuradze, E. / Modebadze, I. / Nebieridze, G. et al. | 2014
- S208
-
P422 SERUM HYALURONIC ACID AS A NON-INVASIVE TOOL TO DIAGNOSE SCHISTOSOMAL PERIPORTAL FIBROSIS IN SCHISTOSOMA MANSONI ENDEMIC AREAS OF ETHIOPIAHaile, F. M. / Berhe, N. et al. | 2014
- S211
-
P431 BRAF AND FHIT EXPRESSION IN HCV RELATED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA AND THEIR ASSOCIATION WITH PROGNOSTIC ANATOMOPATHOLOGICAL FEATURESVidigal, P. V. / Garcia, P. P. / Osório, F. M. / Couto, C. A. / do Carmo, P. A. / de Marco, L. A. et al. | 2014
- S213
-
P438 PEFORMANCE OF LIVER ULTRASOUND IN DIAGNOSING AND ASSESSING THE SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE: A PROSPECTIVE STUDYAlquiroz, R. P. / Cua, I. H. / Bocobo, J. / Cervantes, J. et al. | 2014
- S215
-
P441 PREDICTION OF PORTAL HYPERTENSION AND ESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS WITH APPARENT DIFFUSION COEFFICIENT OF THE SPLEENAbdel Razeka, A. A. / El-Bendary, M. / Motawea, E. / Massoud, S. M. / Abdel-Aziz, M. R. / Zalata, K. et al. | 2014
- S216
-
P444 PREDICTION OF ESOPHAGEAL VARICES USING ACOUSTIC RADIATION FORCE IMPULSE ELASTOGRAPHY IN CIRRHOTIC PATIENTS: DEVELOPMENT AND VALIDATION OF A NOVEL PREDICTIVE MODEL (KOREAN MULTI-CENTER STUDY)Park, Y. / Kim, S. U. / Park, S. Y. / Kim, B. K. / Park, J. Y. / Kim, D. Y. / Ahn, S. H. / Tak, W. Y. / Kweon, Y. O. / Han, K. H. et al. | 2014
- S220
-
P455 BACTERIAL ENDOCARDITIS IN PATIENTS WITH CIRRHOSIS: A MULTICENTER RETROSPECTIVE STUDY OF 78 CASESCadranel, J. F. / Allaire, M. / Blasco-Perrin, H. / Thevenot, T. / Chagneau-Derrode, C. / Pariente, E. A. / Garioud, A. / Lison, H. / Causse, X. / Adhoute, X. et al. | 2014
- S221
-
P458 VALIDATION OF EncephalApp_stroop FOR MINIMAL HEPATIC ENCEPHALOPATHY SCREENING: A MULTI-CENTER US STUDYAllampati, S. / Duarte-Rojo, A. / Thacker, L. / White, M. / Noble, N. / Unser, A. / OShea, R. S. / Flud, C. R. / Klair, J. S. / Bajaj, J. S. et al. | 2014
- S223
-
P464 RESISTANCE TO THROMBOMODULIN IS ASSOCIATED WITH DE NOVO PORTAL VEIN THROMBOSIS AND COULD BE A MODIFIABLE FACTOR TO IMPROVE PROGNOSIS IN PATIENTS WITH CIRRHOSISLa Mura, V. / Tripodi, A. / Cavallaro, F. / Chantarangkul, V. / Colombo, M. / Primignani, M. et al. | 2014
- S224
-
P467 EVALUATION OF CIRRHOTIC CARDIOMYOPATHY IN END STAGE VIRUS C HEPATITIS BY CARDIAC MAGNETIC RESONANCEOmran, D. / Behairy, N. / Mahmoud, M. et al. | 2014
- S225
-
P470 IRON OVERLOAD IN CIRRHOSIS IS ASSOCIATED TO LIVER INSUFFICIENCY AND CIRCULATORY DYSFUNCTION BUT NOT PORTAL HYPERTENSIONRipoll, C. / Keitel, F. / Hollenbach, M. / Zipprich, A. et al. | 2014
- S227
-
P475 ADRENAL INSUFFICIENCY IN CRITICALLY ILL CIRRHOTIC PATIENTS: PREVALENCE, RISK FACTORS AND IMPACT ON MORTALITYNair, H. / Nandish, H. / Shyamsundar, S. / Menon, A. / Mumtaz, K. / Harishkumar, K. / Vallath, B. et al. | 2014
- S228
-
P478 RESOURCE USE ASSOCIATED WITH HEPATIC ENCEPHALOPATHY IN PATIENTS WITH LIVER DISEASEOrr, J. G. / Morgan, C. L. / Jenkins-Jones, S. / Hudson, M. / Conway, P. / Radwan, A. / Currie, C. J. et al. | 2014
- S229
-
P480 COMPARING SCORING SYSTEMS AS A PREDICTOR OF MORTALITY IN ALCOHOLIC HEPATITISSidhu, S. / Reddick, C. / Mcwhirter, K. / Al-Rifai, A. et al. | 2014
- S230
-
P483 CK 18 BASED SERUM APOPTOTIC CELL DEATH MARKER M30 PREDICTS SURVIVAL IN PATIENTS WITH LIVER CIRRHOSISWaidmann, O. / Brunner, F. / Herrmann, E. / Zeuzem, S. / Piiper, A. / Kronenberger, B. et al. | 2014
- S231
-
P487 DETERMINANTS OF RATE OF RISE OF SERUM SODIUM IN CRITICALLY ILL CIRRHOTIC PATIENTS WITH LACTULOSE INDUCED HYPERNATREMIA – A RETROSPECTIVE STUDYRamanarayanan, S. / Nayak, S. / Mathur, R. P. / Sarin, S. K. et al. | 2014
- S232
-
P490 URINARY METABOLIC PROFILING BY H NMR SPECTROSCOPY IN PATIENTS WITH CIRRHOSIS DISCRIMINATES OVERT BUT NOT MINIMAL HEPATIC ENCEPHALOPATHYMcPhail, M. J. / Villa, M. / Cox, I. J. / Williams, R. / Amodio, P. / Montagnese, S. / Taylor-Robinson, S. D. et al. | 2014
- S235
-
P499 ALTERED GUT MICROBIOME IS ASSOCIATED WITH NEURO-INFLAMMATION ON BRAIN MRI IN CIRRHOSIS: IMPLICATIONS FOR THE GUT–LIVER–BRAIN AXISBajaj, J. S. / Ahluwalia, V. S. / Sikaroodi, M. / Wade, J. / White, M. / Heuman, D. / Gilles, H. / Unser, A. / Hylemon, P. / Gillevet, P. M. et al. | 2014
- S239
-
P510 GASTROINTESTINAL ISCHEMIA IN PATIENTS WITH ACUTE AND CHRONIC PORTAL VEIN THROMBOSISHarki, J. / Plompen, E. P. / van Noord, D. / Hoekstra, J. / Kuipers, E. J. / Janssen, H. L. / Tjwa, E. T. et al. | 2014
- S240
-
P513 A SIMPLE MODEL FOR THE PREDICTION OF OVERT HEPATIC ENCEPHALOPATHY IN CIRRHOTIC PATIENTS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY AND VALIDATION IN AN INDEPENDENT COHORTPasquale, C. / Nardelli, S. / Pentassuglio, I. / Gioia, S. / Onori, E. / Piazza, N. / Amodio, P. / De Rui, M. / Schiff, S. / Farcomeni, A. et al. | 2014
- S241
-
P516 Pro-C5: A NOVEL SEROLOGICAL MARKER OF TRUE TYPE V COLLAGEN FORMATION DETECTS PORTAL HYPERTENSION IN CIRRHOSISLeeming, D. J. / Nielsen, M. J. / Karsdal, M. A. / Veidal, S. S. / Trebicka, J. / Bendtsen, F. / Krag, A. / Møller, S. et al. | 2014
- S242
-
P519 CD133+ HEMATOPOIETIC STEM CELLS REINFUSION IN END-STAGE LIVER DISEASE (ESLD): FINAL RESULTS OF A PHASE I CLINICAL TRIALMargini, C. / Brodosi, L. / Lorenzini, S. / Catani, L. / Giudice, V. / Giordano, R. / Casadei, A. / Sollazzo, D. / Foschi, F. G. / Baccarani, M. et al. | 2014
- S243
-
P521 PROPOSAL FOR A NEW, STEPWISE ALGORITHM COMBINING LIVER AND SPLEEN STIFFNESS AND LOK SCORE FOR DIAGNOSIS OF LARGE ESOPHAGEAL VARICES IN PATIENTS WITH LIVER CIRRHOSISStefanescu, H. / Procopet, B. / Platon Lupsor, M. / Maniu, A. / Radu, C. et al. | 2014
- S244
-
P524 COMPARISON OF DIFFERENT MODELS IN PREDICTING CLINICALLY SIGNIFICANT PORTAL HYPERTENSION INCLUDING ELF-SCORE AND vWF-AgMaieron, A. / Hametner, S. / Ferlitsch, M. / Etschmaier, A. / Schoefl, R. / Ziachehabi, A. / Trubert-Exinger, D. / Ferlitsch, A. et al. | 2014
- S245
-
P527 ACUTE CHANGES IN PORTAL PRESSURE GRADIENT (PPG) AFTER PTFE-COVERED TIPS IN CIRRHOTIC PATIENTS WITH PORTAL HYPERTENSIVE COMPLICATIONS: INTRAINDIVIDUAL COMPARISON OF 6-mm AND 8-mm STENT DILATATIONLuca, A. / Miraglia, R. / Maruzzelli, L. / DAmico, M. / Tuzzolino, F. et al. | 2014
- S246
-
P530 FACTORS ASSOCIATED WITH ADIPONECTIN SERUM LEVELS IN PATIENTS WITH LIVER CIRRHOSISSilva, T. E. / Silva, M. C. / Alencar, M. L. / Coelho, M. S. / Wildner, L. M. / Bazzo, M. L. / Chica, D. A. / Dantas-Correa, E. B. / Narciso-Schiavon, J. L. / Schiavon, L. L. et al. | 2014
- S247
-
P534 SPECTRUM AND OUTCOME OF BACTERIAL INFECTIONS AT ADMISSION IN PATIENTS WITH ALCOHOLIC AND NON-ALCOHOLIC CIRRHOSISSahney, A. / Jindal, A. / Vyas, T. / Philip, C. / Vashishtha, C. / Taneja, S. / Khillan, V. / Sarin, S. K. et al. | 2014
- S248
-
P537 eLAAR (THE ENHANCED LIVER ABDOMINAL AREA RATIO): HOW TO USE CROSS-SECTIONAL IMAGING TO ASSESS PROGNOSIS IN END-STAGE CIRRHOSISAlam, S. / Farrell, C. / Fernando, R. / Patanwala, I. / Cross, T. J. et al. | 2014
- S249
-
P540 HEMODYNAMIC CHANGES IN CIRRHOTIC PATIENTS FOLLOWING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) INSERTION: A MATCHED ANALYSISForde, K. A. / McLean, R. C. / Rivera, M. / Tanapanpanit, O. / Soulen, M. / Reddy, K. R. et al. | 2014
- S250
-
P543 INCREASED DNA DAMAGE IN HEPATITIS C VIRUS RELATED HEPATOCELLULAR CARCINOMAShawki, S. / Meshaal, S. / El Dash, A. / Zayed, N. / Hanna, M. et al. | 2014
- S251
-
P547 LOCAL RECURRENCE IN THE TUMOR BLOOD DRAINAGE AREA AFTER RADIOFREQUENCY ABLATIONHirooka, M. / Ochi, H. / Koizumi, Y. / Hiraoka, A. / Tada, F. / Miyake, T. / Tokumoto, Y. / Abe, M. / Hiasa, Y. et al. | 2014
- S254
-
P557 THE RED CELL DISTRIBUTION WIDTH (RDW) IS A NOVEL POWERFUL, INEXPENSIVE PREDICTOR OF SURVIVAL FOR PATIENTS WHO PRESENT WITH HEPATOCELLULAR CARCINOMAGrossi, G. / Smirne, C. / Burlone, M. E. / Pinato, D. J. / Minisini, R. / Pirisi, M. et al. | 2014
- S255
-
P559 CONTINENTAL DIFFERENCES AMONG HIV-INFECTED PATIENTS WITH HEPATOCELLULAR CARCINOMA: EUROPE VS. NORTH AMERICAVentura, M. / Badshah, M. B. / Harris, M. / Merchante, N. / Chen, T. Y. / Qazi, N. / Vispo, E. / Tossonian, H. / Klinker, H. / Marks, K. et al. | 2014
- S256
-
P562 ASSESSMENT OF MALIGNANT POTENTIAL OF HEPATIC HYPOVASCULAR NODULES USING COMBINATION IMAGING STUDIES IN PATIENTS WITH CHRONIC LIVER DISEASETanaka, Y. / Nakazawa, T. / Minamino, T. / Takada, J. / Okuwaki, Y. / Watanabe, M. / Hidaka, H. / Akitaka, S. / Keiji, M. / Wasaburo, K. et al. | 2014
- S257
-
P565 EXPRESSIONS OF EUKARYOTIC TRANSLATION INITIATION FACTOR 3M AND MACROPHAGE MIGRATION INHIBITORY FACTOR IN HAPATOCELLULAR CARCINOMAJeong, J. S. / Han, S. Y. / Ju, M. H. / Paik, Y. H. / Lee, S. W. et al. | 2014
- S258
-
P568 VIROLOGICAL AND CLINICO-PATHOLOGICAL FACTORS IN PREDICTING RECURRENCE OF HEPATITIS B RELATED HEPATOCELLULAR CARCINOMA AFTER SURGICAL RESECTIONHung, I. F. / Wong, D. K. / Fong, D. Y. / Chui, A. H. / Seto, W. / Fung, J. Y. / Yuen, J. C. / Tiu, R. / Choi, O. / Lai, C. L. et al. | 2014
- S259
-
P571 GADOLINIUM ETHOXYBENZYL DIETHYLENETRIAMINEPENTAACETIC ACID MAGNETIC RESONANCE IMAGING AND CONTRAST ENHANCED ULTRASONOGRAPHY WITH SONAZOID AS PART OF THERAPEUTIC STRATEGIES FOR SMALL NONHYPERVASCULAR HEPATIC NODULAR LESIONSTsuchiya, K. / Yasui, Y. / Takada, H. / Nakakuki, N. / Matsuda, S. / Kaneko, S. / Muraoka, M. / Yamashita, K. / Hattori, N. / Tamaki, N. et al. | 2014
- S260
-
P574 HIGH SENSITIVITY C-REACTIVE PROTEIN IS AN INDEPENDENT PREDICTOR FOR RECURRENCE AND SURVIVAL AFTER CURATIVE TREATMENT AMONG PATIENTS WITH HCV-RELATED HEPATOCELLULAR CARCINOMA IN EARLY STAGEFujiwara, N. / Tateishi, R. / Nakagomi, R. / Kondo, M. / Minami, T. / Sato, M. / Uchino, K. / Enooku, K. / Nakagawa, H. / Kondo, Y. et al. | 2014
- S262
-
P580 NONINVASIVE BLOOD FIBROSIS INDICES PREDICT INTRAHEPATIC RECURRENCE AFTER CURATIVE RESECTION OF HEPATOCELLULAR CARCINOMAChoi, W. M. / Lee, J. H. / Cho, Y. Y. / Lee, M. / Yoo, J. J. / Cho, Y. / Lee, D. H. / Lee, Y. B. / Yu, S. J. / Kim, Y. J. et al. | 2014
- S263
-
P583 TELOMERE DYSFUNCTION AND TELOMERASE MUTATIONS ARE RISK FACTORS FOR HEPATOCELLULAR CARCINOMATeixeira, A. C. / Scatena, N. F. / Santana-Lemos, B. A. / Gutierrez, F. R. / Barros, A. C. / Secaf, M. / Calado, R. T. / Martinelli, A. L. et al. | 2014
- S266
-
P592 3,3′-DIINDOLYLMETHANE MODULATES THE IMBALANCE OF TREGS TO Th17 CELLS DURING LIVER FIBROGENESIS THROUGH ACTIVATING THE ARYL HYDROCARBON RECEPTOR AND INHIBITING TOLL-LIKE RECEPTOR 4Liu, Y. / Jiang, W. et al. | 2014
- S267
-
P595 THE EXPRESSION AND FUNCTION OF THE TNF SUPERFAMILY LIGAND, TWEAK AND ITS RECEPTOR FN14 IN LIVER FIBROSISWilhelm, A. / Munir, M. / Humphreys, E. H. / Adams, D. H. / Burkly, L. C. / Afford, S. C. / Weston, C. J. et al. | 2014
- S268
-
P598 ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) GENE THERAPY USING A HIGH EFFICIENCY AND LIVER-SPECIFIC ADENO-ASSOCIATED VIRAL VECTOR ATTENUATES EXPERIMENTAL LIVER FIBROSIS IN MICEMak, K. Y. / Chin, R. / Torresi, J. / Cunningham, S. C. / Alexander, I. E. / Angus, P. W. / Herath, C. B. et al. | 2014
- S269
-
P601 CCR6 DEFICIENCY ENHANCES LIVER INFLAMMATION AND FIBROSIS BY MODULATING HEPATIC MACROPHAGES M1/M2 BALANCE AND INFLAMMATORY CELLS RECRUITMENTAffò, S. / Rodrigo-Torres, D. / Blaya, D. / Morales-Ibanez, O. / Millán, C. / Arroyo, V. / Caballería, J. / Ginès, P. / Bataller, R. / Sancho-Bru, P. et al. | 2014
- S273
-
P613 THE EXTRACELLULAR PROTEINASE Expi/Wfdc18 IS INDUCED BY TOLL-LIKE RECEPTOR 9 (TLR9) IN MACROPHAGES AND ENHANCES HEPATIC FIBROGENESISLiebe, R. / Hall, R. / Dooley, S. / Lammert, F. et al. | 2014
- S274
-
P617 MECHANOSENSITIVE SIGNALLING VIA Yap/Taz DURING HEPATIC STELLATE CELL ACTIVATIONPritchett, J. P. / Martin, K. / Llewellyn, J. / Henderson, D. / Athwal, V. / Hanley, N. / Piper Hanley, K. et al. | 2014
- S275
-
P620 THE AMPK-RELATED KINASE, Nuak2 IS MODULATED BY THE ACTIVATION PROCESS AND REGULATES MOTILITY OF HEPATIC STELLATE CELLS (HSC)Tosti-Guerra, C. / Caligiuri, A. / Provenzano, A. / Rombouts, K. / Bertolani, C. / Pinzani, M. / Marra, F. et al. | 2014
- S276
-
P623 NCU-G1GT/GT MICE: A LONG-LIVED MODEL FOR LIVER FIBROSISKong, X. Y. / Nesset, C. K. / Schjalm, C. / Løberg, E. M. / Rustan, A. C. / Thoresen, G. H. / Kase, E. T. / Eskild, W. et al. | 2014
- S277
-
P627 ANALYSIS OF METABOLIC ACTIVITIES IN FETAL AND ADULT HUMAN HEPATOCYTES FOR CLINICAL THERAPYGramignoli, R. / Strom, S. C. et al. | 2014
- S278
-
P630 AUTOPHAGY REGULATES HEPATOCYTES DIFFERENTIATION DURING EPITHELIAL TO MESENCHYMAL (EMT) AND MESENCHYMAL TO EPITHELIAL TRANSITION (MET) BY PROMOTING SNAIL DEGRADATIONGrassi, G. / Di Caprio, G. / Santangelo, L. / Komatsu, M. / Fimia, G. M. / Piacentini, M. / Tripodi, M. / Alonzi, T. et al. | 2014
- S279
-
P633 REGULATION OF LIVER FIBROSIS BY TUNING M2 MACROPHAGE POLARIZATION THROUGH IL-4Rα INHIBITIONWeng, S. Y. / Padberg, K. / Wang, X. Y. / Kim, Y. O. / Crosby, J. / McCaleb, M. / Schuppan, D. et al. | 2014
- S280
-
P636 A SCORING SYSTEM FOR PREDICTING SIGNIFICANT FIBROSIS IN CHRONIC HEPATITIS B PATIENTS WITH NORMAL OR MILDLY ELEVATED ALANINE AMINOTRANSFERASE LEVELSWang, H. / Yan, R. / Zhou, Y. / Ru, G. Q. / Wang, M. S. et al. | 2014
- S282
-
P643 HEPATITIS B SURFACE ANTIGEN IN LATE HEPATITIS B INFECTIONZeng, D. W. / Zhu, Y. Y. / Dong, J. / Jiang, J. J. / Liu, Y. R. et al. | 2014
- S283
-
P646 DETECTABLE HEVRNA IN PATIENTS WITH A SEROLOGICAL PROFILE CONSISTENT WITH PREVIOUS INFECTIONHaywood, B. / Tedder, R. S. / Ijaz, S. et al. | 2014
- S284
-
P649 HIGH VIPERIN mRNA EXPRESSION IN THE LIVER IS PREDICTIVE OF HDVRNA LOSS IN HBV/DELTA CO-INFECTED PATIENTSCarey, I. / Hughes, S. A. / Shang, D. / Childs, K. / Bruce, M. / Horner, M. / Fletcher, I. / Joshi, D. / Harrison, P. M. / Agarwal, K. et al. | 2014
- S285
-
P652 CLINICAL CHARACTERISTICS OF HEPATITIS B VIRUS REACTIVATION IN A PROSPECTIVE LONG-TERM STUDY FOR PATIENTS WITH HEMATOLOGIC MALIGNANCYTamori, A. / Hino, M. / Kawamura, E. / Hagihara, A. / Fujii, H. / Uchida-Kobayashi, S. / Iwai, S. / Morikawa, H. / Nakamae, H. / Enomoto, M. et al. | 2014
- S286
-
P655 GENDER DIFFERENCE IN THE EFFECT OF HEPATITIS B VIRUS GENOTYPE ON DISEASE PROGRESSIONJeng, R. W. / Chen, Y. C. / Liaw, Y. F. et al. | 2014
- S287
-
P658 LOW RISK OF HEPATITIS B VIRUS REACTIVATION IN HBsAg NEGATIVE, ANTI-HBc POSITIVE CARRIERS UNDERGOING RITUXIMAB FOR RHEUMATOID ARTHRITISViganò, M. / Varisco, V. / Lampertico, P. / Batticciotto, A. / Mascheroni, A. / Gibertini, P. / Pellerito, R. / Rovera, G. / Caporali, R. / Todoerti, M. et al. | 2014
- S288
-
P661 APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALSKim, W. R. / Berg, T. / Asselah, T. / Flisiak, R. / Fung, S. / Gordon, S. / Janssen, H. L. / Lampertico, P. / Lau, D. / Bornstein, J. D. et al. | 2014
- S290
-
P666 PREDICTORS OF SEVERE HEPATIC FIBROSIS IN TREATMENT-NAIVE GENOTYPE B OR C INFECTED E ANTIGEN-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B PATIENTSSu, W. P. / Peng, C. Y. / Lai, H. C. / Lin, C. H. / Chuang, P. H. / Chen, S. H. et al. | 2014
- S291
-
P669 A GENOME-WIDE ASSOCIATION STUDY ON PERSISTENT HBV INFECTION AND ITS CLINICAL SIGNIFICANCE IN MALE HAN-TAIWANESEChang, S. W. / Fann, C. S. / Su, W. H. / Wang, Y. C. / Weng, C. C. / Yu, C. J. / Hsu, C. L. / Hsieh, A. R. / Chien, R. N. / Chu, C. M. et al. | 2014
- S292
-
P672 HBeAg LEVELS DIFFER ACCORDING TO HBV GENOTYPE IN IMMUNE CLEARANCE DISEASEBayliss, J. / Thompson, A. / Rosenberg, G. / Gaggar, A. / Kitrinos, K. / Gane, E. / Chan, H. L. / Li, X. / Littlejohn, M. / Yuen, L. et al. | 2014
- S293
-
P674 SERUM LEVELS OF HEPATITIS B SURFACE ANTIGEN PREDICT LONG-TERM TRAJECTORIES OF HEPATITIS B VIRAL LOADLiu, J. / Yang, H. I. / Chen, C. F. / Lee, M. H. / Batrla-Utermann, R. / Jen, C. L. / Lu, S. N. / Wang, L. Y. / You, S. L. / Chen, C. J. et al. | 2014
- S294
-
P677 HEPATIC STEATOSIS DOES NOT PREDICT REGRESSION OF LIVER CIRRHOSIS IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)Buti, M. / Washington, M. K. / Gane, E. / Aguilar Schall, R. / Bornstein, J. D. / Subramanian, M. / McHutchison, J. G. / Flisiak, R. / Janssen, H. L. / Marcellin, P. et al. | 2014
- S295
-
P680 A NATIONAL HEALTH SYSTEM RESPONSE TO CHRONIC HEPATITIS B: USING POPULATION DATA TO DEFINE GAPS IN CLINICAL CARE PROVISIONAllard, N. / MacLachlan, J. H. / Cowie, B. et al. | 2014
- S296
-
P683 INFLUENCE OF A NTCP RECEPTOR GENE POLYMORPHISM ON HEPATITIS B VIRUS (HBV) INFECTIONDietz, J. / Knop, V. / Vermehren, J. / Füller, C. / Perner, D. / Hüppe, D. / Mauss, S. / Zeuzem, S. / Sarrazin, C. et al. | 2014
- S297
-
P686 EXTRAHEPATIC REPLICATION OF HEPATITIS E VIRUS IN HUMAN PLACENTA: ITS CLINICAL IMPLICATIONSDeka, P. / Das, B. C. / Hazam, R. K. / Kumar, A. / Kar, P. et al. | 2014
- S298
-
P689 DIFFERENTIATION OF PATIENTS WITH HBeAg NEGATIVE HEPATITIS VERSUS HBeAg NEGATIVE INACTIVE CARRIER STATUS BY SERUM CYTOKINES AND CHEMOKINESWiegand, S. B. / Wranke, A. / Falk, C. / Deterding, K. / Manns, M. P. / Wedemeyer, H. / Cornberg, M. et al. | 2014
- S299
-
P692 HIGH NORMAL ALT AND BORDERLINE HBVDNA WERE PREDICTORS FOR FUTURE TREATMENT ELIGIBILITY IN CHRONIC HEPATITIS B (CHB) PATIENTS WHO INITIALLY DID NOT MEET CRITERIAUribe, L. / Nguyen, N. / Nguyen, L. / Kim, L. H. / Trinh, H. N. / Nguyen, M. H. et al. | 2014
- S300
-
P695 APPLICATION OF TAQMAN LOW-DENSITY ARRAYS FOR SIMULTANEOUS RAPID DETECTION OF MULTIPLE PATHOGENS ASSOCIATED WITH JAUNDICEHeaney, J. / Davies, S. E. / Alexander, G. J. / Curran, M. D. et al. | 2014
- S302
-
P701 AUTOCHTHONOUS ACUTE HEPATITIS E IN SWITZERLAND: INCREASED RATE OF SEVERE MANIFESTATION IN MEN >50 YEARSDoerig, C. / Moulin, H. / Müllhaupt, B. / Pache, I. / Bihl, F. / Telenti, A. / Sahli, R. / Moradpour, D. et al. | 2014
- S303
-
P704 CLINICAL COURSE AND TREATMENT OF CHRONIC HEPATITIS E INFECTION IN PATIENTS AFTER SOLID ORGAN TRANSPLANTATIONHalilbasic, E. / Kazemi-Shirazi, L. / Staufer, K. / Munda, P. / Müller, C. J. / Holzmann, H. / Jaksch, P. / Klepetko, W. / Trauner, M. / Hofer, H. et al. | 2014
- S305
-
P710 EFFECT OF ALISPORIVIR (ALV) ON THE PHARMACOKINETICS (PK), SAFETY, AND TOLERABILITY OF METHADONE IN HEALTHY SUBJECTS AND OPIOID-DEPENDENT PATIENTS ON STABLE METHADONE MAINTENANCE THERAPY (MMT)Kovacs, S. J. / Ke, J. / Barve, A. / Webster, L. R. / Cheng, Y. / Zhang, J. / Maietta, R. / Sunkara, G. / Stein, D. S. et al. | 2014
- S306
-
P713 ELIGIBILITY 1: A PROSPECTIVE, OBSERVATIONAL, MULTICENTRE STUDY EVALUATING HCV PATIENTS CHARACTERISTICS OF ELIGIBILITY FOR ANTIVIRAL THERAPY IN REAL CLINICAL PRACTICEGamal, N. / Vukotic, R. / Andreone, P. et al. | 2014
- S309
-
P721 INTERFERON-STIMULATED GENE EXPRESSION IS ASSOCIATED WITH TREATMENT RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTIONDatsenko, Y. / Baum, P. / Schirmbeck, R. / Stern, J. O. / Sha, N. / Steinmann, G. G. et al. | 2014
- S310
-
P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIESAsselah, T. / Jensen, D. M. / Foster, G. R. / Sulkowski, M. S. / Ouzan, D. / Morano, L. / Buynak, R. / Agarwal, K. / Hassanein, T. / Forton, D. et al. | 2014
- S311
-
P725 IMPACT OF THE rs8099917 SNP ON SVR12 IN PATIENTS WITH HCV GT-1 INFECTION TREATED WITH FALDAPREVIR, DELEOBUVIR AND RIBAVIRINAsselah, T. / Zeuzem, S. / Soriano, V. / Bronowicki, J. P. / Lohse, A. W. / Müllhaupt, B. / Schuchmann, M. / Bourlière, M. / Buti, M. / Roberts, S. et al. | 2014
- S312
-
P729 HCV GENOTYPE 1A AND 1B: SIMILARITIES AND DIFFERENCES IN CLINICAL FEATURES, THERAPEUTIC OUTCOME AND PREDICTORS OF RESPONSEMorisco, F. / Di Marco, V. / Granata, R. / Camera, S. / Ippolito, A. / Margaglione, M. / Fattovich, G. / Smedile, A. / Clery, E. / Ferraiuoli, C. et al. | 2014
- S314
-
P734 A SYSTEMATIC REVIEW OF INTERVENTIONS TO REDUCE ALCOHOL CONSUMPTION AMONG INDIVIDUALS WITH CHRONIC HCV INFECTIONDoyle, J. S. / Hunt, D. / Aspinall, E. J. / Hutchinson, S. J. / Goldberg, D. J. / Nguyen, T. / Falck-Ytter, Y. / Morgan, R. L. / Smith, B. / Stoove, M. et al. | 2014
- S316
-
P740 PHARMACOKINETICS OF FALDAPREVIR IN HEALTHY SUBJECTS FOLLOWING CO-ADMINISTRATION WITH ITRACONAZOLEMarzin, K. / Koenen, R. / Strelkowa, N. / Kammerer, K. P. / Elgadi, M. / Huang, F. et al. | 2014
- S318
-
P745 SEQUENCING OF INITIAL AND RECURRENT HCV INFECTIONS IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN (MSM)Macartney, M. / Ricciardi, A. / Rodger, A. / Webster, D. / Karageorgopoulos, D. / Fernandez, T. / Ferro, F. / Sasadeusz, J. / Bhagani, S. et al. | 2014
- S319
-
P746 VITAMIN D RELATED PATHWAY GENE POLYMORPHISMS ENHANCED THE PREDICTION OF TREATMENT RESPONSE IN ASIAN CHRONIC HEPATITIS C-INFECTED PATIENTS WITH UNFAVORABLE IL-28B rs12979860 GENOTYPESThanapirom, K. / Suksawatamnuay, S. / Sukeepaisarnjaroen, W. / Tangkijvanich, P. / Treeprasertsuk, S. / Thaimai, P. / Akkarathamrongsin, S. / Poovorawan, Y. / Kullavanijaya, P. / Komolmit, P. et al. | 2014
- S320
-
P749 HIGH BURDEN OF FIBROSIS AND METABOLIC COFACTORS IN A COHORT OF PREDOMINANTLY GENOTYPE 3-INFECTED INJECTION DRUG USERS IN SOUTHERN INDIAMehta, S. H. / Solomon, S. S. / Srikrishnan, A. K. / McFall, A. / Bose, K. / Nandagopal, P. / Anand, S. / Kumar, M. S. / Thomas, D. L. / Solomon, S. et al. | 2014
- S321
-
P752 GENETIC POLYMORPHISM IN PNPLA3 GENE IMPACTS DISEASE PROGRESSION AND HEPATOCELLULAR CARCINOMA DEVELOPMENT IN CHRONIC HEPATITIS CKurosaki, M. / Tsuchiya, K. / Yasui, Y. / Tamaki, N. / Matsuda, S. / Hattori, K. / Izumi, N. et al. | 2014
- S323
-
P759 CD100 EXPRESSION ON B CELLS IS ASSOCIATED WITH CONTROL OF HEPATITIS C VIRUS INFECTIONGuo, Y. H. / He, Y. / Chen, L. / Zhou, Y. / Fan, C. / Zhang, Y. / Lian, J. Q. / Hao, C. Q. / Jia, Z. S. et al. | 2014
- S324
-
P762 TEMPORAL CHANGES IN HEPATITIS C VIRUS GENOTYPE 3A DISTRIBUTION AMONG PEOPLE WHO INJECT DRUGS IN VANCOUVER, CANADAJacka, B. / Applegate, T. / Poon, A. F. / Harrigan, R. / Dore, G. J. / Olmstead, A. / DeBeck, K. / Milloy, M. J. / Lamoury, F. / Woods, C. et al. | 2014
- S325
-
P765 DRIED BLOOD SPOTS (DBS), A PROMISING TOOL FOR LARGE-SCALE HEPATITIS C SCREENING, DIAGNOSIS AND TREATMENT MONITORINGChevaliez, S. / Soulier, A. / Poiteau, L. / Pawlotsky, J. M. et al. | 2014
- S327
-
P772 CD14+ MONOCYTES AND CD163+ MACROPHAGES CORRELATE WITH THE SEVERITY OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS CZhao, S. / Wang, R. / Zhang, Y. / Meng, P. / Kong, L. / Nan, Y. et al. | 2014
- S328
-
P775 HEPATITIS C VIRUS INFECTION AND THE ASSOCIATED RISK FOR DIABETES MELLITUSShaw, G. T. / Lee, M. H. / Yang, H. I. / Jen, C. L. / Lu, S. N. / Wang, L. Y. / You, S. L. / LItalien, G. / Yuan, Y. / Chen, C. J. et al. | 2014
- S329
-
P778 RESOURCE UTILIZATION DURING HEPATITIS C TREATMENT WITH BOCEPREVIR- OR TELAPREVIR-BASED TRIPLE THERAPY VS DUAL THERAPY IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATIONNyberg, L. M. / Chiang, K. M. / Li, Z. / Nyberg, A. H. / Younossi, Z. M. / Cheetham, T. C. et al. | 2014
- S331
-
P784 INTERLEUKIN-18 AND ITS GENE POLYMORPHISMS INFLUENCE THE PROGRESSION OF CHRONIC HEPATITIS CSaid, E. M. / Soliman, M. S. / Rashed, M. S. / Abo El Azm, A. A. / Zakaria, R. / Abd El Salam, F. M. et al. | 2014
- S333
-
P790 REDUCING THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN ENGLANDRosenberg, W. M. / Cramp, M. / Davis, M. / Parkes, J. / Ryder, S. / Razavi, H. / Hindman, S. et al. | 2014
- S334
-
P793 VALIDATION OF FATTY LIVER INDEX FOR IDENTIFYING FATTY LIVER IN A LARGE-SCALE CROSS-SECTIONAL STUDY IN POPULATIONS SEEKING CHECK-UP IN TAIWANSu, C. W. / Wang, Y. J. / Wu, J. C. / Huo, T. I. / Huang, Y. H. / Lee, K. C. / Lin, H. C. / Lee, F. Y. / Lee, S. D. et al. | 2014
- S336
-
P800 A CLOSE ASSOCIATION BETWEEN LOCALIZATION OF OXIDIZED PHOSPHOLIPIDS AND EXPRESSION OF TUMOR NECROSIS FACTOR ALPHA IN LIVERS OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASEIkura, Y. / Iwai, Y. / Muragaki, Y. et al. | 2014
- S338
-
P804 ASSOCIATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE AND ESTIMATED GLOMERULAR FILTRATION RATE IN APPARENTLY HEALTHY POPULATIONShen, Z. / Qin, Y. / Zhu, H. / Yu, C. / Li, Y. et al. | 2014
- S339
-
P807 EVALUATION OF THE FATTY LIVER INDEX (FLI) IN A MULTIETHNIC UNITED STATES POPULATIONRuhl, C. E. / Everhart, J. E. et al. | 2014
- S340
-
P809 PATIENTS WITH T2DM ACCOMPANYING SEVERE DEGREE OF NAFLD ASSESSED BY CONTROLLED ATTENUATION PARAMETER USING FIBROSCANChon, Y. E. / Kim, K. / Jung, K. S. / Kim, S. U. / Park, J. Y. / Kim, D. Y. / Ahn, S. H. / Chon, C. Y. / Han, K. H. et al. | 2014
- S341
-
P813 MODERATE ALCOHOL CONSUMPTION HAS A PROTECTIVE EFFECT ON INSULIN RESISTANCE IN NON-OBESE HEPATITIS C-INFECTED PATIENTSBurman, B. E. / Khalili, M. et al. | 2014
- S342
-
P816 MERTK rs4374383 AA GENOTYPE IS ASSOCIATED WITH A LOWER PREVALENCE OF SEVERE HEPATIC STEATOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASEPetta, S. / Valenti, L. / Grimaudo, S. / Tripodo, C. / Cammà, C. / Di Marco, V. / Dongiovanni, P. / Fargion, S. / Guarnotta, C. / Gulino, A. et al. | 2014
- S343
-
P819 PREDICTIVE FACTORS OF SIGNIFICANT STEATOSIS IN POTENTIAL HEALTHY LIVER DONORSJothimani, D. / Srivatsav, M. / Reddy, S. / Rela, M. et al. | 2014
- S344
-
P822 MULTIPARAMETRIC MAGNETIC RESONANCE SHOWS THAT OBESITY IS STRONGLY ASSOCIATED WITH HEPATIC STEATOSIS IN ADULTS AND CHILDREN AND CAN DIFFERENTIATE PATIENTS WITH NASH FROM NAFLDBanerjee, R. / Rial, B. / Pavlides, M. / Osuchukwu, C. / Lewandowski, A. J. / Collier, J. D. / Schneider, J. E. / Neubauer, S. / Barnes, E. et al. | 2014
- S345
-
P824 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASEKazankov, K. / Barrera, F. / Møller, H. J. / Vilstrup, H. / George, J. / Grønbæk, H. et al. | 2014
- S346
-
P828 THE COMMON PNPLA3 VARIANT IS ASSOCIATED WITH HEPATIC STEATOSIS QUANTIFIED BY CONTROLLED ATTENUATION PARAMETER AND DETERMINES THE FATE OF PATIENTS WITH CHRONIC LIVER DISEASESArslanow, A. / Stokes, C. S. / Weber, S. N. / Grünhage, F. / Lammert, F. / Krawczyk, M. et al. | 2014
- S347
-
P831 MAGNETIC RESONANCE IMAGING ALLOWS QUANTITATION OF HEPATIC TRIGLYCERIDE CONCENTRATION IN HUMANSJiménez-Agüero, R. / Emparanza, J. I. / Beguiristain, A. / Bujanda, L. / Alustiza, J. M. / García, E. / Hijona, E. / Gallego, L. / Sánchez, J. / Perugorria, M. et al. | 2014
- S348
-
P833 QUERCETIN MODULATES LIPIDS DROPLETS IN Huh7 CELLS BEARING PNPLA3 GENOTYPE GGRojas, A. / Rancha, I. / García-Valdecasas, M. / Del Campo, J. A. / Clement, S. / Negro, F. / Romero-Gomez, M. et al. | 2014
- S349
-
P834 NON-INVASIVE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASEGallego-Durán, R. / Cerro-Salido, P. / Pareja, M. J. / Ranchal, I. / Rico, M. C. / Rojas, L. / Aznar, R. / Bugianesi, E. / Crespo, J. / Arias-Loste, M. T. et al. | 2014
- S350
-
P837 GENOTYPE 3 AND CIRCULATING SCCA-IgM ARE INDEPENDENTLY ASSOCIATED WITH HISTOLOGICAL FEATURES OF NASH IN HCV INFECTED PATIENTSMartini, A. / Fattovich, G. / Guido, M. / Bugianesi, E. / Biasiolo, A. / Ieluzzi, D. / Gallotta, A. / Fassina, G. / Merkel, C. / Gatta, A. et al. | 2014
- S352
-
P843 ALTERATION IN GLUCOSE METABOLISM AFTER AN ORAL GLUCOSE LOAD AND RELATIONSHIP WITH LIVER DAMAGE IN PATIENTS WITH NAFLDVanni, E. / Mezzabotta, L. / Rosso, C. / Gaggini, M. / Gambino, R. / Salomone, F. / Buzzigoli, E. / Saponaro, C. / Saba, F. / Ciociaro, D. et al. | 2014
- S353
-
P846 SERUM FREE FATTY ACID COMPOSITION IS ASSOCIATED WITH DIFFERENT DEGREES OF FIBROSISGambino, R. / Alemanno, N. / Pinach, S. / Saba, F. / Mezzabotta, L. / Rosso, C. / Vanni, E. / Bugianesi, E. / Cassader, M. et al. | 2014
- S354
-
P849 QUANTITATIVE AND QUALITATIVE ANALYSIS OF PLASMA FREE FATTY ACIDS AND THEIR IMPACT ON LIVER DAMAGE IN NAFLD PATIENTSSaponaro, C. / Vanni, E. / Gaggini, M. / Rosso, C. / Mezzabotta, L. / Gambino, R. / Buzzigoli, E. / Carli, F. / Abate, M. L. / Saba, F. et al. | 2014
- S355
-
P852 WHY GGT LEVELS SHOULDNT BE DISREGARDED WHEN CONSIDERING A PATIENT WITH POSSIBLE NAFLDBarsic, N. / Radic, D. / Marusic, Z. / Palcic, M. G. / Stojsavljevic, S. / Duvnjak, M. et al. | 2014
- S357
-
P857 A NEW INDEX OF GLUTATHIONE TURNOVER (GSH_TI) AND ITS ASSOCIATION WITH SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)Gaggini, M. / Saponaro, C. / Vanni, E. / Rosso, C. / Carli, F. / Buzzigoli, E. / Abate, M. L. / Ciociaro, D. / Mezzabotta, L. / Gambino, R. et al. | 2014
- S358
-
P860 NUCLEAR RECEPTOR FXR UPREGULATES GENE EXPRESSION OF BILE ACID TRANSPORTERS IN NONALCOHOLIC STEATOHEPATITISMéndez-Sánchez, N. / Sánchez-Valle, V. / López-Velázquez, J. A. / Chablé-Montero, F. / Chávez-Tapia, N. C. / Uribe, M. et al. | 2014
- S362
-
P867 FACTORS PREDICTING OUTCOME OF PATIENTS WITH ACUTE LIVER FAILURE MEETING THE CRITERIA OF LIVER TRANSPLANTATION: IMPACT OF ALBUMIN DIALYSIS WITH MARSSaliba, F. / Dahlqvist, G. / Letierce, A. / Ichai, P. / Ruiz, I. / Boudon, M. / Samuel, D. et al. | 2014
- S363
-
P871 SIGNIFICANTLY INCREASED POST-LIVER TRANSPLANTATION MORTALITY AMONG PATIENTS AGE 70 YEARS AND OLDERWong, R. J. / Ahmed, A. / Esquivel, C. et al. | 2014
- S364
-
P873 EARLY RENAL DYSFUNCTION AFTER LIVER TRANSPLANTATION IS ASSOCIATED WITH REDUCED GRAFT AND PATIENT SURVIVALBhanji, R. / Ma, M. / Bain, V. G. / Montano-Loza, A. J. et al. | 2014
- S365
-
P877 INCREASED GRAFT FAILURE WITH DONATION AFTER CARDIAC DEATH VERSUS DONATION AFTER BRAIN DEATH GRAFTS IN LIVER TRANSPLANT RECIPIENTS WITH HEPATITIS C: AN UPDATED META-ANALYSISWells, M. / Janik, T. / Chandok, N. et al. | 2014
- S366
-
P880 TERTIARY CENTRE EXPERIENCE OF THE SAFETY AND EFFICACY OF ANTI-TNFS FOR ULCERATIVE COLITIS (UC) AFTER LIVER TRANSPLANTATIONBarnabas, A. / Potts, J. / Agarwal, K. / Hayee, B. et al. | 2014
- S367
-
P882 COMBINED OR NOT COMBINED LIVER/KIDNEY TRANSPLANTATION FOR SYMPTOMATIC POLYCYSTIC LIVER DISEASE: SINGLE CENTER LONG-TERM OUTCOME EXPERIENCETemmerman, F. / Ceulemans, L. J. / Monbaliu, D. / Aerts, R. / van Pelt, J. / Darius, T. / Kuypers, D. / Pirenne, J. / Nevens, F. et al. | 2014
- S368
-
P884 DONOR/RECIPIENT GENDER MISMATCH MODIFIES THE IMPACT OF DONOR AGE ON GRAFT SURVIVAL FOLLOWING LIVER TRANSPLANTATIONBitetto, D. / Pecere, S. / Gambato, M. / Ferrarese, A. / Pasulo, L. / Lucà, M. G. / Poli, E. / Corradini, S. G. / Baccarani, U. / Burra, P. et al. | 2014
- S369
-
P886 RELEVANCE OF CHRONIC HEPATITIS E IN LIVER TRANSPLANT RECIPIENTS: A REAL-LIFE-SETTINGGalante, A. / Pischke, S. / Lang, M. / Lütgehetmann, M. / Polywka, S. / Nashan, B. / Lohse, A. W. / Sterneck, M. et al. | 2014
- S370
-
P889 NEW NUCLEOS(T)IDE ANALOGUE MONOPROPHYLAXIS AFTER HEPATITIS B IMMUNOGLOBULIN WITHDRAWAL IS SAFE AND EFFECTIVE AGAINST HEPATITIS B RECURRENCE AFTER LIVER TRANSPLANTATIONCholongitas, E. / Goulis, J. / Antoniadis, N. / Fouzas, I. / Imvrios, G. / Vasiliadis, T. / Papanikolaou, V. / Akriviadis, E. et al. | 2014
- S371
-
P892 PREVALENCE OF DONOR SPECIFIC ANTIBODIES IN LIVER TRANSPLANTATION RECIPIENTS WITH UNEXPLAINED LIVER GRAFT ABNORMALITIES IS SIGNIFICANTLY HIGHER THAN IN CONTROL GROUPSGhandir, A. / Carmagnat, M. / Zafrani, E. S. / Roudot-Thoraval, F. / Hurtova, M. / Mallat, A. / Desvaux, D. / Féray, C. / Suberbielle, C. / Duvoux, C. et al. | 2014
- S372
-
P895 MODEL TO PREDICT RECURRENCE AFTER LIVING DONOR LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA BEYOND THE MILAN CRITERIALee, J. H. / Cho, Y. / Lee, D. H. / Lee, Y. B. / Yu, S. J. / Yi, N. J. / Lee, K. W. / Kim, S. H. / Kim, Y. J. / Yoon, J. H. et al. | 2014
- S373
-
P897 THE PREDICTORS OF TRANSPLANT FREE SURVIVAL IN FULMINANT AUTOIMMUNE ACUTE LIVER FAILURE: THE ACUTE LIVER FAILURE STUDY GROUP EXPERIENCEGanger, D. / Stravitz, R. T. / Reddy, K. R. / Battenhouse, H. / Speiser, J. / Lominadze, Z. / Lee, W. et al. | 2014
- S374
-
P900 LIVER TRANSPLANTATION FOR ALCOHOLIC CIRRHOSIS WITH RESPECT TO ALCOHOL RELAPSE AND LONG-TERM OUTCOMEBerlakovich, G. A. / Kollmann, D. / Rasoul-Rockenschaub, S. / Freundorfer, E. / Gyoeri, G. / Silberhumer, G. / Muehlbacher, F. / Soliman, T. et al. | 2014
- S375
-
P903 CONTROL OF DIABETES MELLITUS (DM) IN LIVER TRANSPLANT RECIPIENTS (LTR)Rodríguez-Medina, B. / Satorres, C. / Álvarez, D. / Herrero, I. / Serrano, T. / De la Mata, M. / Aguilera, V. / Rubín, . / Berenguer, M. et al. | 2014
- S376
-
P905 THE RISK OF DELISTING OR DEATH IN LIVER TRANSPLANT CANDIDATES INCREASES FOLLOWING INFECTIONS: RESULTS FROM THE NACSELD CONSORTIUMOLeary, J. G. / Bajaj, J. S. / Wong, F. / Kamath, P. S. / Biggins, S. W. / Patton, H. M. / Fallon, M. B. / Garcia-Tsao, G. / Subramanian, R. M. / Maliakkal, B. J. et al. | 2014
- S377
-
P908 EVEROLIMUS TREATMENT IN LIVER TRANSPLANTATION ACCORDING TO CLINICAL PRACTICE: A SPANISH MULTICENTRE COHORTCastroagudín, J. / Salcedo, M. / Bilbao, I. / Gómez, M. A. / Jimenez, C. / Fabregat, J. / Almohalla, C. / Herrero, I. / Cuervas-Mons, V. / Otero, A. et al. | 2014
- S378
-
P911 GLOMERULAR FILTRATION RATE DETERMINED BY CKD-EPI-CYSTATIN C EQUATION, BUT NOT WITH MDRD4 OR CKD-EPI-CREATININ, IS ASSOCIATED WITH LONG TERM SURVIVAL AFTER LIVER TRANSPLANTATIONUguen, T. / Jezequel, C. / Houssel, P. / Latournerie, M. / Boudjema, K. / Guyader, D. / Bardou-Jacquet, E. et al. | 2014
- S379
-
P914 MICROBIOLOGICAL ANALYSIS OF BILE DURING CHOLANGIOGRAPHY IN LIVER TRANSPLANT RECIPIENTS AND ITS IMPACT ON THE MANAGEMENT OF INFECTIOUS COMPLICATIONSHüsing, A. / Beckebaum, S. / Cicinnati, V. R. / Wilms, C. / Maschmeier, M. / Schmidt, H. H. / Kabar, I. et al. | 2014
- S380
-
P917 PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION: A SINGLE CENTRE EXPERIENCEStradella, D. / Risso, A. / Martini, S. / Rizzetto, M. / Salizzoni, M. et al. | 2014
- S381
-
P920 DOES PRE-TRANSPLANT ADRENAL FUNCTION HAVE AN IMPACT ON POST-TRANSPLANT RENAL FUNCTION?Saffioti, F. / Theocharidou, E. / OBeirne, J. / Agarwal, B. / Thorburn, D. / Jeffrey, G. / Burroughs, A. K. et al. | 2014
- S382
-
P923 RETROSPECTIVE STUDY COMPARING SAFETY AND EFFICACY OF GENERIC PREPARATION OF TACROLIMUS WITH PROGRAF AS PRIMARY IMMUNOSUPPRESSION AFTER LIVER TRANSPLANTATIONPasangulapati, S. / Featherstone, B. / Allison, M. E. et al. | 2014
- S383
-
P926 ASSOCIATION OF PRIMARY PAYER STATUS AND IN-HOSPITAL MORTALITY AMONG LIVER TRANSPLANT RECIPIENTS: A NATIONAL PERSPECTIVEMazumder, N. K. / Mujib, N. / Mujib, M. et al. | 2014
- S384
-
P929 HEPATIC FUNCTION AND DETERIORATION IN HEPATIC FUNCTION BY QUANTITATIVE LIVER-SPLEEN SCAN (QLSS) INDEPENDENTLY PREDICT CLINICAL EVENTS (CE): A SECONDARY ANALYSIS OF THE HALT-C TRIALHoefs, J. C. / Chen, W. P. / Gillen, D. et al. | 2014
- S385
-
P932 CIRRHOTIC CARDIOMYOPATHY MANIFESTED BY LEFT VENTRICULAR DIASTOLIC DYSFUNCTION (LVDD) – A RISK FACTOR IN THE DEVELOPMENT OF HEPATORENAL SYNDROME (HRS)Zaidi, Y. A. / Ali, B. / Salim, A. / Adil, M. / Alam, A. / Butt, A. K. / Malik, K. / Amin, J. / Dilshad, A. et al. | 2014
- S388
-
P941 REDUCTION IN SERUM SODIUM (Na) IN PATIENTS TREATED WITH TERLIPRESSIN FOR VARICEAL BLEEDING (VB) AND HEPATORENAL SYNDROME (HRS)Sugumaran, A. / Lougher, E. / Halpin-Evans, C. / Czajkowski, M. A. / Yeoman, A. D. et al. | 2014
- S389
-
P943 DIFFERENCES IN CREATININE BETWEEN GENDERS COULD DISADVANTAGE INFECTED CIRRHOTIC WOMEN: THE NACSELD EXPERIENCEBajaj, J. S. / OLeary, J. / Reddy, K. R. / Wong, F. / Fallon, M. / Biggins, S. / Patton, H. / Maliakkal, B. / Thuluvath, P. / Garcia-Tsao, G. et al. | 2014
- S390
-
P946 COMPARISON OF THE EFFICACY OF RIFAXIMIN VS NORFLOXACIN IN THE PREVENTION OF NOSOCOMIAL MULTIRESISTANT BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSISRamos, J. M. / Vidal, I. / Bellot, P. / Francés, R. / González-Navajas, J. / Zapater, P. / Such, J. et al. | 2014
- S391
-
P949 QUANTITATION AND LOCATION OF THE SEVERITY OF BRAIN EDEMA IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE AND HEPATIC ENCEPHALOPATHYWeiss, N. / Rosselli, M. / Mouri, S. / Yu, D. / Galanaud, D. / Agarwal, B. / Thabut, D. / Jalan, R. et al. | 2014
- S392
-
P952 IODINATED CONTRAST IS NOT A RISK FACTOR FOR KIDNEY DYSFUNCTION IN STABLE CIRRHOTIC PATIENTS UNDERGOING ELECTIVE IMAGINGSafi, W. / Rauscher, I. / Umgelter, A. et al. | 2014
- S393
-
P955 IN VITRO COMPARISON OF Octaplas-LG, STANDARD Octaplas AND FRESH FROZEN PLASMA IN THE TREATMENT OF COAGULOPATHY DUE TO LIVER DISEASEConnaughton, M. A. / Chin, J. L. / Mc Cormack, P. A. / OBrien, P. / Fitzgerald, J. M. et al. | 2014
- S398
-
P971 VITAMIN K DOSING AND BRANCHED CHAIN AMINO ACIDS SUPPLEMENTATION COULD IMPROVE THE PROGNOSIS OF SORAFENIB-TREATED PATIENTS WITH HEPATOCELLULAR CARCINOMAHaruna, Y. / Inoue, A. et al. | 2014
- S401
-
P980 AN EXTERNAL VALIDATION OF THE HEPATOMA ARTERIAL-EMBOLISATION PROGNOSIS (HAP) SCORE: THE LIVERPOOL EXPERIENCENoorullah, O. / Lekharaju, V. P. / Din, I. U. / Klcova, J. / Cross, T. / Evans, J. / Sturgess, R. / Palmer, D. / Kumar, P. / OGrady, E. et al. | 2014
- S402
-
P983 VALIDATION OF THE HEPATOME ARTERIAL-EMBOLIZATION PROGNOSTIC (HAP)-SCORE IN AN AUSTRIAN TACE COHORTPinter, M. / Hucke, F. / Graziadei, I. / Vogel, W. / Trauner, M. / Sieghart, W. / Peck-Radosavljevic, M. et al. | 2014
- S405
-
P993 EASL AND MRECIST RESPONSE TO COMBINATION THERAPY OF SORAFENIB AND TRANSARTERIAL CHEMOEMBOLIZATION PREDICTS SURVIVAL IN HEPATOCELLULAR CARCINOMAWang, W. / Bai, W. / Zhao, Y. / Yin, Z. / He, C. / Niu, J. / Liu, L. / Chen, H. / Fan, D. / Han, G. et al. | 2014
- S406
-
P996 PROPOSAL FOR AN UPDATE OF THE BARCELONA STAGING SYSTEM FOR HEPATOCELLULAR CARCINOMA BASED ON THE ROLE OF PERFORMANCE STATUSPecorelli, A. / Vitale, A. / Venerandi, L. / Cucchetti, A. / Trevisani, F. / Bolondi, L. / Piscaglia, F. et al. | 2014
- S407
-
P999 Y90-RADIOEMBOLIZATION FOR INTERMEDIATE/ADVANCED HCC PATIENTS OUTSIDE THE CONVENTIONAL CRITERIA MAY BE DETRIMENTAL: A SINGLE CENTER EXPERIENCESposito, C. / Facciorusso, A. / Camerini, T. / Chiesa, C. / Maccauro, M. / Morosi, C. / Bhoori, S. / Citterio, D. / Mazzaferro, V. et al. | 2014
- S408
-
P1002 TREATMENT ALLOCATION AND SURVIVAL ACCORDING TO THE NEW BCLC-B SUB-CLASSIFICATION MODEL IN HEPATOCELLULAR CARCINOMA. EXPERIENCE IN A TERTIARY ROMANIAN GASTROENTEROLOGICAL AND SURGICAL CENTERSparchez, Z. A. / Radu, P. / Al Hajjar, N. / Iancu, C. et al. | 2014
- S409
-
P1005 TRANSIENT ELASTOGRAPHY BASED CIRRHOSIS SCORE SIGNIFICANTLY IMPROVING EFFICIENCY OF COMPENSATED HEPATITIS B CIRRHOSIS DETECTIONChen, Y. P. / Dai, L. / Peng, J. / Zhu, Y. F. et al. | 2014
- S411
-
P1011 ACOUSTIC RADIATION FORCE IMPULSE-IMAGING IN COMPARISON TO TRANSIENT ELASTOGRAPHY FOR NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS C: A PROSPECTIVE INTERNATIONAL MULTICENTER STUDYFriedrich-Rust, M. / Lupsor-Platon, M. / de Knegt, R. / Dries, V. / Buggisch, P. / Gebel, M. / Maier, B. / Herrmann, E. / Sagir, A. / Zachoval, R. et al. | 2014
- S412
-
P1013 MEASUREMENT OF LIVER AND SPLEEN STIFFNESS BY ARFI ELASTOGRAPHY: INTRA- AND INTER-OBSERVER VARIABILITY AND PREDICTORS OF VARIABILITYBalakrishnan, M. / Souza, F. / Munoz, C. / Augustin, S. / Loo, N. / Deng, Y. / Ciarleglio, M. / Garcia-Tsao, G. et al. | 2014
- S414
-
P1019 VALIDATION AND COMPARISON OF NON-INVASIVE MARKERS OF LIVER FIBROSIS IN WEST-AFRICAN PATIENTS WITH CHRONIC HEPATITIS B LIVING IN THE GAMBIALemoine, M. / Shimakawa, Y. / Goldin, R. / Khalil, M. / Lloyd, J. / Suso, P. / Nayagam, S. / Freeya Njai, H. / Taal, M. / Ndow, G. et al. | 2014
- S415
-
P1022 QUANTIFICATION OF FIBROSIS IN CHRONIC HEPATITIS C: PERFORMANCE OF TRANSIENT ELASTOGRAPHY AND ACOUSTIC RADIATION FORCE IMPULSE USING COLLAGEN PROPORTIONATE AREA AS REFERENCECalvaruso, V. / Di Marco, V. / Bronte, F. / Bavetta, M. G. / Alessi, N. / Cammà, C. / Craxì, A. et al. | 2014
- S417
-
P1029 LIVER STIFFNESS (LS) ASSESSED WITH ACOUSTIC RADIATION FORCE IMPULSE (ARFI) CAN BE PROGNOSTIC FOR FIRST EPISODE OF ASCITES (AD) IN PATIENTS AFFECTED BY CHRONIC LIVER DISEASE (CLD)De Santis, A. / Bassanelli, C. / Lupo, M. / Iegri, C. / Di Ciesco, C. / Forlino, M. / Gallusi, G. / Attili, A. F. et al. | 2014
- S418
-
P1032 LOW ACCURACY OF NON-INVASIVE TESTS FOR ASSESSING RESIDUAL CIRRHOSIS IN HEPATITIS C PATIENTS WITH A SUSTAINED VIROLOGICAL RESPONSEDegasperi, E. / Grassi, E. / Fraquelli, M. / Aghemo, A. / DAmbrosio, R. / Colombo, M. et al. | 2014
- S419
-
P1034 ESTIMATED PREVALENCE OF HCV CIRRHOSIS IN THE CHRONIC HEPATITIS COHORT STUDY (CHECS)Gordon, S. C. / Lamerato, L. / Rupp, L. B. / Holmberg, S. D. / Moorman, A. C. / Spradling, P. R. / Teshale, E. / Vijayadeva, V. / Boscarino, J. A. / Schmidt, M. A. et al. | 2014
- S420
-
P1037 NON-INVASIVE MODALITIES FOR THE DIAGNOSIS OF ADVANCED FIBROSIS AND CIRRHOSIS IN CHRONIC HEPATITIS B OR CJeng, R. W. / Tsay, P. K. / Chen, W. T. / Huang, C. H. / Lin, S. M. / Tai, D. I. et al. | 2014
- S421
-
P1040 TENOFOVIR FOR THE PROPHYLAXIS OF HBV REACTIVATION IN ANTI-HBC-POSITIVE PATIENTS WITH HEMATOLOGIC MALIGNANCIES TREATED WITH RITUXIMAB: PRELIMINARY RESULTS OF A RANDOMIZED STUDY (PREBLIN STUDY)Buti, M. / Morillas, R. / Manzano, M. L. / García-Retortillo, M. / Gutiérrez, M. L. / Martín, L. / Prieto, M. / Suárez, E. / Gea, F. / Rodríguez, M. et al. | 2014
- S423
-
P1045 ESTIMATING THE PROBABILITY OF RESPONSE TO PEG-INTERFERON THERAPY IN HBeAg-POSITIVE CHRONIC HEPATITIS B: THE EPIC-B STUDYSonneveld, M. J. / Wong, V. W. / Piratvisuth, T. / Jia, J. D. / Zeuzem, S. / Gane, E. / Liaw, Y. F. / Xie, Q. / Chan, H. L. / Hansen, B. E. et al. | 2014
- S424
-
P1047 ENTECAVIR EFFECTIVENESS IN NAIVE AND NUC EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B AND LIVER CIRRHOSIS: INTERIM ANALYSIS OF THE ITALIAN ENTAS COHORT STUDYPorro, E. / Di Leo, A. / Marzano, A. / Brancaccio, G. / Maimone, S. / Fasano, M. / Grasso, A. / Bronte, F. / Fagiuoli, S. / Santantonio, T. et al. | 2014
- S425
-
P1050 LONG-TERM OUTCOME OF SEQUENTIAL THERAPY WITH LAMIVUDINE FOLLOWED BY INTERFERON IN NUCLEOSIDE-NAIVE, HEPATITIS B E ANTIGEN-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B VIRUS GENOTYPE C INFECTIONEnomoto, M. / Nishiguchi, S. / Tamori, A. / Uchida-Kobayashi, S. / Iwai, S. / Morikawa, H. / Murakami, Y. / Jomura, H. / Shiomi, S. / Kawada, N. et al. | 2014
- S426
-
P1052 DETERMINANTS OF VARIABILITY IN ISG15 GENE EXPRESSION IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) INFECTION DURING TREATMENT WITH ORAL TLR7 AGONIST GS-9620Gane, E. J. / Gordon, S. / Kottili, S. / Massetto, B. / Gaggar, A. / Stem, S. / Pflanz, S. / Ye, Z. / Subramanian, M. / McHutchison, J. G. et al. | 2014
- S427
-
P1054 NEED FOR EDUCATIONAL PROGRAMS AND SUPPORT DURING ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B IN IMMIGRANTS. EVIDENCE FROM THE CATALAN GIV-2002/2012-CHB THERAPEUTIC COHORTAcero Fernandez, D. / Ferri Iglesias, M. J. / López Nuñez, C. / Barenys Lacha, M. / Louvriex Freire, R. / Peñafiel Muñoz, J. / Fábregas Tió, S. / Lopez Oliu, C. / Vidal Plana, L. / Hombrados Verde, M. et al. | 2014
- S428
-
P1056 CHARACTERIZATION OF A NATURALLY OCCURRING REPLICATION-COMPETENT DEFECTIVE INTERFERING-LIKE HEPATITIS D VIRUS RNA LACKING BOTH RIBOZYME SITESHsu, C. W. / Chao, M. / Chen, Y. C. / Chang, M. L. / Huang, S. F. / Yeh, C. T. et al. | 2014
- S429
-
P1059 PORTAL HYPERTENSION BUT NOT HCC RISK IS ATTENUATED IN COMPENSATED CIRRHOTICS FOLLOWING 10 YEARS OF TREATMENT WITH NUCLEOS(T)IDE ANALOGSInvernizzi, F. / Lampertico, P. / Mangia, G. / Iavarone, M. / Viganò, M. / Primignani, M. / De Franchis, R. / Colombo, M. et al. | 2014
- S432
-
P1067 RESPONSE-GUIDED PEGINTERFERON ALFA-2a (PegIFN alfa-2a) THERAPY IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B (CHB)Hou, J. / Ma, H. / Sun, J. / Xie, Q. / Xie, Y. / Sun, Y. / Wang, H. / Shi, G. / Wan, M. / Niu, J. et al. | 2014
- S433
-
P1070 FIRST LINE TREATMENT FOR CHRONIC HEPATITIS B (CH-B) IN REAL LIFE. AN ITALIAN MULTICENTER OBSERVATIONAL COHORT (HBV-RER)Borghi, V. / Andreone, P. / Massari, M. / Villa, E. / Pietrangelo, A. / Verucchi, G. / Levantesi, F. / Ferrari, C. et al. | 2014
- S434
-
P1073 PEGINTERFERON-INDUCED HEPATITIS B SURFACE ANTIGEN SEROCLEARANCE AND SEROREVERSION IN CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON: A LONG-TERM FOLLOW-UP STUDYLuo, K. / Liu, Z. / He, H. / Yang, G. et al. | 2014
- S436
-
P1078 PREDICTION OF EVS PRESENCE BY CALCULATED RISK SCORES IN B-VIRAL CIRRHOSISMarietti, M. / Debernardi Venon, W. / Sciandrello, M. C. / Reggiani, S. / Fasulo, R. / Marengo, A. / Rizzetto, M. / Marzano, A. et al. | 2014
- S437
-
P1081 VACCINE ESCAPE MUTANTS AND SUBOPTIMAL HEPATITIS B VIRUS RESPONSE IN HIV–HBV COINFECTED PATIENTS FROM SUB-SAHARAN AFRICABoyd, A. / Moh, R. / Dény, P. / Issoufou, M. / Danel, C. / Anglaret, X. / Eholié, S. / Girard, P. M. / Zoulim, F. / Lacombe, K. et al. | 2014
- S438
-
P1084 PRESENCE OF STEATOSIS AND HBeAg-POSITIVE STATUS ARE INDEPENDENTLY ASSOCIATED WITH PERSISTENTLY ELEVATED SERUM ALT LEVELS IN CHRONIC HBV PATIENTS DURING ANTIVIRAL THERAPYJacobson, I. M. / Washington, M. K. / Thompson, A. / Afdhal, N. H. / Aguilar Schall, R. / Dinh, P. / Bornstein, J. / Flaherty, J. F. / Subramanian, G. M. / McHutchison, J. G. et al. | 2014
- S441
-
P1092 SEQUENTIAL THERAPY WITH TENOFOVIR AND PEGYLATED INTERFERON-ALPHA2b VERSUS TENOFOVIR MONOTHERAPY IN HBeAg POSITIVE CHRONIC HEPATITIS B (CHB): AN INTERIM ANALYSISJindal, A. / Kumar, M. / Sarin, S. K. et al. | 2014
- S442
-
P1095 HBVRNA IN SERUM IS A PREDICTOR OF HBeAg SEROCONVERSION IN PATIENTS WITH CHRONIC HEPATITIS B RECEIVING TREATMENT WITH PEG-INTERFERON ALPHA-2a (40KD)van Bömmel, F. / van Bömmel, A. / He, H. / Wat, C. / Deichsel, D. / Berg, T. / Böhm, S. et al. | 2014
- S445
-
P1103 IMPACT OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL ON RESPONSE TO TELAPREVIR-BASED TRIPLE THERAPY FOR CHRONIC HEPATITIS C PATIENTSOgawa, E. / Furusyo, N. / Nakamuta, M. / Kajiwara, E. / Nomura, H. / Dohmen, K. / Takahashi, K. / Satoh, T. / Azuma, K. / Kawano, A. et al. | 2014
- S446
-
P1107 TYPES AND PREDICTORS OF INTERFERON/RIBAVIRIN INDUCED CARDIAC COMPLICATIONS IN THE EGYPTIAN PATIENTS WITH CHRONIC HEPATITIS C VIRUSEl-Dosouky, I. / ElHawari, S. / Emara, M. / Hamed, E. et al. | 2014
- S448
-
P1111 ANRS HC15 NRFI: LONG-TERM MAINTENANCE THERAPY WITH A COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON IN CHRONIC HEPATITIS C. RESULTS OF A MULTICENTER RANDOMIZED CONTROLLED TRIALGuyader, D. / Bellissant, E. / Asselah, T. / Bronowicki, J. P. / Abergel, A. / Lasser, L. / Tran, A. / Bourlière, M. / Samuel, D. / Wartelle, C. et al. | 2014
- S449
-
P1114 PATIENT-REPORTED OUTCOMES (PROS) IN CHRONIC HEPATITIS C PATIENTS WITH CIRRHOSIS TREATED WITH SOFOSBUVIR (SOF) CONTAINING REGIMENSYounossi, Z. M. / Stepanova, M. / Nader, F. / Nelson, D. / Lawitz, E. / Jacobson, I. M. / Gane, E. / Hunt, S. L. et al. | 2014
- S450
-
P1117 SIMEPREVIR REDUCES TIME WITH PEGINTERFERON/RIBAVIRIN-INDUCED SYMPTOMS AND QUALITY-OF-LIFE IMPAIRMENTS: 72-WEEK RESULTS FROM THREE PHASE III STUDIESScott, J. / Gilles, L. / Peeters, M. / Cerri, K. / Beumont-Mauviel, M. et al. | 2014
- S452
-
P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALSFerenci, P. / Dieterich, D. / Zeuzem, S. / Mantry, P. / Sarrazin, C. / Crespo, J. / Tam, E. / Dufour, J. F. / Yoshida, E. M. / Nishiguchi, S. et al. | 2014
- S453
-
P1123 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS INFECTED WITH HCV GENOTYPE 1: INTERIM RESULTS FROM THE TriCo STUDYFerenci, P. / Flisiak, R. / Caruntu, F. A. / Lengyel, G. / Hohmann, M. / Bakalos, G. et al. | 2014
- S454
-
P1125 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF TWO PHASE III TRIALSFoster, G. R. / Cooper, C. / Dieterich, D. / Ferenci, P. / Crespo, J. / Diago, M. / Dufour, J. F. / Lee, W. M. / Maevskaya, M. / Müllhaupt, B. et al. | 2014
- S457
-
P1130 FUTILITY TESTING AT TREATMENT WEEK 8 IN PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION RECEIVING BOCEPREVIR: A POST HOC ANALYSISJacobson, I. M. / Silva, M. / Bruno, S. / Calleja, J. L. / Bacon, B. / Esteban, R. / Poordad, F. / Bronowicki, J. P. / Sulkowski, M. S. / Vierling, J. M. et al. | 2014
- S458
-
P1132 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSEAsselah, T. / Zehnter, E. / Agarwal, K. / Sakai, Y. / Yatsuhashi, H. / Willems, B. / Wright, D. / Calinas, F. / Calleja, J. L. / Negro, F. et al. | 2014
- S459
-
P1134 DURATION OF UNDETECTABLE HCVRNA IN PATIENTS TREATED WITH FALDAPREVIR–DELEOBUVIR INTERFERON-FREE COMBINATION IS ASSOCIATED WITH SVRDufour, J. F. / Zeuzem, S. / Buti, M. / Bronowicki, J. P. / Buynak, R. / Müllhaupt, B. / Mantry, P. / Bourlière, M. / Taunk, J. / Stern, J. O. et al. | 2014
- S460
-
P1136 TRIPLE THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING: IS IT POSSIBLE TO ACHIEVE SVR RATES COMPARABLE TO PIVOTAL TRIALS?Buggisch, P. / Schober, A. / Bruch, H. R. / Antoni, C. / Loehr, H. / Herrmann, A. / Steffens, H. / Moog, G. / Haessner, J. / Hoerster, H. G. et al. | 2014
- S462
-
P1141 SUSTAINED VIROLOGICAL RESPONSE (SVR) IN HCV TREATMENT-EXPERIENCED PATIENTS AFTER TRIPLE THERAPY WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTINGBoeker, K. H. / Link, R. / Baumgarten, A. / Stoehr, A. / Heyne, R. / Roessle, M. / Schott, E. / Ullrich, R. / Erren, P. / Herold, C. et al. | 2014
- S463
-
P1144 DETERMINING THE COMPARATIVE EFFECTIVENESS OF EMERGING TREATMENT REGIMENS FOR HEPATITIS C VIRUS (HCV) INFECTION FROM SINGLE ARM PHASE III TRIALSQuintana, M. / Broglio, K. / Daar, E. S. / Yuan, Y. / Kalsekar, A. / Detry, M. A. / Lewis, R. J. / Le, T. / Berry, S. M. et al. | 2014
- S464
-
P1147 OUTCOMES AND COSTS OF TREATING HEPATITIS C WITH PROTEASE INHIBITORS: RESULTS FROM A MULTI-CENTRE STUDYStahmeyer, J. T. / Rossol, S. / Bert, F. / Abdelfattah, A. M. / Mauss, S. / Heyne, R. / John, C. / Pape, S. / Schober, A. / Teuber, G. et al. | 2014
- S465
-
P1149 PHYSICIAN ADHERENCE TO AND EFFICACY OF TRIPLE THERAPY WITH TELAPREVIR (TVR) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN (PEGIFN/RBV) IN A REAL-LIFE SETTINGMauss, S. / Schober, A. / John, C. / Lutz, T. / Moog, G. / Bruch, H. R. / Teuber, G. / Christensen, S. / Heyne, R. / Pape, S. et al. | 2014
- S468
-
P1156 DACLATASVIR, ASUNAPREVIR, AND BMS-791325 IN A FIXED-DOSE COMBINATION: A PHASE 1 BIOAVAILABILITY STUDY IN HEALTHY VOLUNTEERSAdamczyk, R. / Sims, K. / Chang, I. / Filoramo, D. / Pursley, J. / Charlton, S. / Koo, O. / Bertz, R. / Rege, B. / AbuTarif, M. et al. | 2014
- S472
-
P1165 STANDARD INTERFERON – DOWN BUT NOT OUTChoudhry, A. A. / Alam, A. / Nawaz, A. A. / Riaz, M. / Yousaf, I. / Alvi, A. et al. | 2014
- S473
-
P1168 ITPA AND SLC29A1 GENOTYPING BEFORE TRIPLE THERAPY PREDICT SEVERITY OF RIBAVIRIN-INDUCED ANEMIAMilazzo, L. / Landonio, S. / Magni, C. / Gervasoni, C. / Calvi, E. / Cheli, S. / Clementi, E. / Galli, M. / Falvella, F. S. et al. | 2014
- S475
-
P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSISNaggie, S. / Sulkowski, M. / Gaggar, A. / Stamm, L. / Ni, L. / Brainard, D. / Symonds, W. / McHutchison, J. / Dieterich, D. / Rodriguez-Torres, M. et al. | 2014
- S478
-
P1180 CAN A LIFESTYLE MODIFICATION INTERVENTION IMPROVE RISK FACTORS FOR A NEGATIVE RESPONSE TO PEGINTERFERON TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C, CIRRHOSIS AND OBESITY?Agarwal, A. / Pattullo, V. / Garcia-Saenz-de-Sicilia, M. / Sockalingam, S. / Fantus, I. G. / Allard, J. P. / Heathcote, E. J. / Feld, J. J. / Duarte-Rojo, A. et al. | 2014
- S479
-
P1182 RELATIONSHIP OF LEPTIN AND ADIPONECTIN LEVELS WITH EXPRESSION OF ADR1 AND ADR2, VIRAL LOAD AND INFECTING HCV-GENOTYPE IN MEXICAN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTIONRincon-Sanchez, A. R. / Rios-Guerra, M. A. / Cordero Perez, P. / Muñoz Espinosa, L. E. / Islas-Carbajal, M. C. / Rivs-Estilla, A. M. et al. | 2014
- S481
-
P1186 TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE-1 HCV INFECTION: PHARMACOKINETIC RESULTS OF ADJUSTED DOSING WITH TACROLIMUS OR CYCLOSPORINE IN THE TELAPREVIR REPLACE STUDYForns, X. / Samuel, D. / Mutimer, D. / Fagiouli, S. / Navasa, M. / Agarwal, K. / Berenguer, M. / Colombo, M. / Herzer, K. / Nevens, F. et al. | 2014
- S482
-
P1189 HIGH MIG (CXCL9) PLASMA LEVEL FAVORS RESPONSE TO PEGINTERFERON AND RIBAVIRIN IN HCV INFECTED PATIENTS BUT IS NOT LINKED TO DPP4 ACTIVITYJohansson, S. / Talloen, W. / Tuefferd, M. / Darling, J. / Fanning, G. / Fried, M. W. / Aerssens, J. et al. | 2014
- S483
-
P1192 HEPATITIS C VIRUS (HCV) RELATED KNOWLEDGE AND WILLINGNESS TO RECEIVE TREATMENT AMONG PATIENTS ON METHADONE MAINTENANCEZeremski, M. / Dimova, R. B. / Zavala, R. / Kritz, S. / Lin, M. / Smith, B. D. / Zibbell, J. / Talal, A. H. et al. | 2014
- S484
-
P1194 EVALUATION OF OPTIMAL HCV RNA CUT-OFFS WITH TWO MAJOR REAL-TIME PCR-BASED ASSAYS FOR RESPONSE-GUIDED TRIPLE THERAPY WITH TELAPREVIRSarrazin, C. / Dierynck, I. / Cloherty, G. / Ghys, A. / Janssen, K. / Van Eygen, V. / Luo, D. / Witek, J. / Buti, M. / Picchio, G. et al. | 2014
- S485
-
P1196 ADVERSE EFFECTS OF TRIPLE THERAPY WITH BOCEPREVIR (BOC) AND TELAPREVIR (TVR) IN CLINICAL PRACTICE IN PATIENTS WITH ADVANCED HEPATIC FIBROSISSalmerón, J. / Pons, J. / Quiles, R. / Pascasio, J. / Carmona, I. / Simón, M. / Gila, A. / Sánchez Antolín, G. / Sousa, J. / Serra, M. et al. | 2014
- S486
-
P1198 EFFECTIVENESS OF TRIPLE THERAPY IN CLINICAL PRACTICE FOR TREATMENT-NAIVE HCV PATIENTS WITH ADVANCED HEPATIC FIBROSIS. VIROLOGIC RESPONSE DATA AT 12 WEEKS POST-TREATMENT (SVR-12W)Prieto, M. / Pascasio, J. / Vinaixa, C. / Gila, A. / Serra, M. / Ruiz Escolano, E. / Cuaresma, M. / Urquijo, J. / Millán, R. / Sánchez Ruano, J. et al. | 2014
- S488
-
P1202 EARLY PREDICTION OF SUSTAINED VIROLOGIC RESPONSE BY HCV CORE ANTIGEN KINETICS IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON PLUS RIBAVIRINRicco, G. / Moriconi, F. / Colombatto, P. / Oliveri, F. / Cavallone, D. / Ciccorossi, P. / Coco, B. / Romagnoli, V. / Rastelli, C. / Cherubini, B. et al. | 2014
- S489
-
P1205 ELIGIBILITY 2: A PROSPECTIVE, OBSERVATIONAL, MULTICENTRE STUDY EVALUATING THE MANAGEMENT AND OUTCOMES OF PEG-INTERFERON/RIBAVIRIN (PEG-IFN/RBV) TREATMENT IN CHRONIC HEPATITIS C (CHC)Vukotic, R. / Gamal, N. / Andreone, P. et al. | 2014
- S490
-
P1208 PREDICTION OF SEVERE CUTANEOUS REACTION DURING TRIPLE THERAPY IN HCV: VALIDATION OF A GWAS CANDIDATE GENETIC MARKERPalescandolo, E. / Vijgen, L. / Talloen, W. / Colombo, M. / Mangia, A. / Wedemeyer, H. / Demasi, R. / Lonjon-Domanec, I. / Aerssens, J. et al. | 2014
- S491
-
P1210 PREDICTORS OF SVR24 FOR 1078 PATIENTS WITH SEVERE FIBROSIS OR COMPENSATED CIRRHOSIS: THE INTERNATIONAL TELAPREVIR ACCESS PROGRAMColombo, M. / Strasser, S. I. / Moreno, C. / Ferreira, P. A. / Urbanek, P. / Fernández, I. / Abdurakhmanov, D. / Streinu-Cercel, A. / Verheyen, A. / Iraqi, W. et al. | 2014
- S494
-
P1219 IMPACT OF IL-28B GENE POLYMORPHISM ON INTRAFAMILIAL TRANSMISSION, AND RESPONSE TO TREATMENT OF HCV. IS IT OF THE SAME IMPORTANCE?Elwan, N. M. / Assal, F. H. / AboAli, L. / Effat, L. / Sayed, K. / Shalaby, S. / Abdel-Hamid, M. et al. | 2014
- S495
-
P1222 A PHASE II STUDY OF SAMATASVIR (IDX719) IN COMBINATION WITH SIMEPREVIR AND RIBAVIRIN IN TREATMENT-NAÏVE HCV-INFECTED SUBJECTS WITH GENOTYPES 1B AND 4 (HELIX-1 STUDY)Lawitz, E. / Rodriguez-Torres, M. / Nguyen, T. / Sheikh, A. / Tobias, H. / Galati, J. / Hill, J. / Lok, A. / Nelson, D. / Dubuc Patrick, G. et al. | 2014
- S496
-
P1225 THE S282T VARIANT IS NOT OBSERVED IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 HCV INFECTION TREATED WITH THE NUCLEOTIDE INHIBITOR VX-135 IN COMBINATION WITH RIBAVIRINTigges, A. / Zhang, E. / Davis, A. / Spanks, J. / Dorrian, J. / Symons, J. / Bartels, D. / Fry, J. / Kieffer, T. et al. | 2014
- S497
-
P1228 COMPARATIVE RESISTANCE ANALYSIS BETWEEN CIRRHOTIC AND NON-CIRRHOTIC TREATMENT EXPERIENCED PATIENTS WHO FAILED TREATMENT WITH A COMBINATION OF VANIPREVIR (MK-7009) AND PEGYLATED INTERFERON AND RIBAVIRIN (P/R)Ludmerer, S. / Barnard, R. / Brunhoffer, J. / Howe, A. / Hwang, P. M. / Liu, R. / Zhou, A. / Mobashery, N. et al. | 2014
- S498
-
P1231 TOO CERTAIN, TOO SOON? INTERPRETING RESULTS FROM EARLY-STAGE HCV CLINICAL TRIALSKing, M. / Xiong, J. et al. | 2014
- S500
-
P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORSCento, V. / Di Maio, V. C. / Di Paolo, D. / Micheli, V. / Tontodonati, M. / De Leonardis, F. / Aragri, M. / Antonucci, F. P. / Mancon, A. / Armenia, D. et al. | 2014
- S501
-
P1238 SVR24 RATE OF 60% IN HCV G1-INFECTED PRIOR NULL RESPONDERS TREATED WITH MERICITABINE (MCB), BOCEPREVIR (BOC) PLUS PEGIFN ALFA-2a/RIBAVIRIN (P/R): RESULTS FROM DYNAMO 1Wedemeyer, H. / Hézode, C. / Lee, S. S. / Scalori, A. / Zhao, S. / Voulgari, A. / Thommes, J. et al. | 2014
- S502
-
P1240 CHARACTERIZATION OF HCV-1 SUBTYPES AND NATURAL RESISTANCE TO PROTEASE INHIBITORS IN LIVER AND PLASMA COMPARTMENTS OF HIV/HCV COINFECTED INDIVIDUALSBagaglio, S. / Messina, E. / Hasson, H. / Merli, M. / Lazzarin, A. / Smacchia, A. / Uberti-Foppa, C. / Morsica, G. et al. | 2014
- S503
-
P1243 SOFOSBUVIR PLUS RIBAVIRIN, AN INTERFERON-FREE REGIMEN, IN THE TREATMENT OF TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC GENOTYPE 4 HCV INFECTIONRuane, P. J. / Ain, D. / Meshrekey, R. / Riad, J. / Soliman, M. / Mikhail, S. / Wolfe, P. R. / Kersey, K. / Doehle, B. / Jiang, D. et al. | 2014
- S504
-
P1246 PHLEBOTOMY FREQUENCY REDUCED BY PROTON PUMP INHIBITORS IN PATIENTS WITH HEREDITARY HEMOCHROMATOSISvan Aerts, R. M. / van Deursen, C. T. / Koek, G. H. et al. | 2014
- S506
-
P1252 EVEROLIMUS HALTS DISEASE PROGRESSION IN A RODENT MODEL OF POLYCYSTIC LIVER DISEASE: RESULTS OF A LONGITUDINAL MRI-STUDYTemmerman, F. / Chen, F. / van Pelt, J. / Mekahli, D. / Levtchenko, E. / Ni, Y. / Nevens, F. et al. | 2014
- S508
-
P1259 PROGNOSIS IN PEDIATRIC ACUTE LIVER FAILURE – PELD VERSUS PRISM III SCORESKhanna, R. / Sood, V. / Alam, S. / Rawat, D. et al. | 2014
- S509
-
P1262 TARGETED NEXT-GENERATION SEQUENCING (NGS) REVEALS NOVEL GENOTYPE AND PHENOTYPE CORRELATIONS FOR MITOCHONDRIAL DNA DEPLETION SYNDROMES IN PEDIATRIC ACUTE LIVER FAILURE (ALF)Valencia, A. C. / Huang, T. / Sheridan, R. / Peters, A. / Bove, K. / Wang, X. / Miethke, A. et al. | 2014
- S511
-
P1267 CLINICAL PRESENTATION OF CYSTIC FIBROSIS-ASSOCIATED LIVER DISEASE AFTER LUNG TRANSPLANTATIONStaufer, K. / Halilbasic, E. / Schick, S. / Harm, S. / Brichta, A. / Ba-Ssalamah, A. / Jaksch, P. / Klepetko, W. / Trauner, M. / Kazemi-Shirazi, L. et al. | 2014
- S512
-
P1270 SEX HORMONES DIFFERENTLY REGULATE HEPATIC HEPCIDIN EXPRESSION AND SYSTEMIC IRON HOMEOSTASIS IN VIVOGaruti, C. / Montosi, G. / Barelli, S. / Pietrangelo, A. / Corradini, E. et al. | 2014
- S513
-
P1273 DIRECT COSTS OF TREATMENT AND CATASTROPHIC HEALTH EXPENDITURE AMONG HBV-RELATED DISEASES AND THE ROLE OF PUBLIC HEALTH INSURANCE IN YUNNAN PROVINCE OF CHINAChe, Y. / Sriplung, H. / Chongsuvivatwong, V. / Li, L. / You, J. et al. | 2014
- S514
-
P1276 5 YEAR REVIEW OF NEWLY IDENTIFIED HEPATITIS B SURFACE ANTIGEN POSITIVE PATIENTS IN A SUBURBAN LONDON DISTRICT GENERAL HOSPITALNayagam, J. S. / Mullender, C. / See, L. M. / Gess, M. et al. | 2014
- S517
-
P1283 PREVALENCE OF LIVER DISEASES IN RUSSIAN MEGALOPOLISKomova, A. / Maevskaya, M. / Ivashkin, V. et al. | 2014
- S518
-
P1286 RAISING THE PROFILE OF END OF LIFE CARE NEEDS FOR PATIENTS DYING FROM LIVER DISEASE – USING NATIONAL MORTALITY DATAPring, A. J. / Verne, J. et al. | 2014
- S520
-
P1292 EVIDENCE OF CONTINUED INJECTING DRUG USE AFTER ATTAINING SUSTAINED TREATMENT-INDUCED CLEARANCE OF THE HEPATITIS C VIRUS: IMPLICATIONS FOR RE-INFECTIONValerio, H. M. / Hutchinson, S. J. / Goldberg, D. J. / Lewsey, J. / Weir, A. / Innes, H. et al. | 2014
- S523
-
O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDYMangia, A. / Marcellin, P. / Kwo, P. / Foster, G. R. / Buti, M. / Bräu, N. / Muir, A. / Yang, J. C. / Mo, H. / Ding, X. et al. | 2014
- S524
-
O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTSManns, M. / Pol, S. / Jacobson, I. / Marcellin, P. / Gordon, S. / Peng, C. Y. / Chang, T. T. / Everson, G. / Heo, J. / Gerken, G. et al. | 2014
- S525
-
O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES – AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTSNevens, F. / Andreone, P. / Mazzella, G. / Strasser, S. / Bowlus, C. / Invernizzi, P. / Drenth, J. / Pockros, P. / Regula, J. / Hansen, B. et al. | 2014
- S527
-
P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDYKao, J. H. / Heo, J. / Yoffe, B. / Sievert, W. / Jacobson, I. / Bessone, F. / Peng, C. Y. / Roberts, S. / Yoon, K. T. / Kopit, J. et al. | 2014
- S528
-
P1303 AN INTERFERON- AND RIBAVIRIN-FREE 12-WEEK REGIMEN OF ONCE-DAILY VX-135 AND DACLATASVIR IN TREATMENT-NAÏVE PATIENTS WITH GENOTYPE 1 HCV INFECTIONGane, E. / Stedman, C. / Garg, V. / George, S. / Kieffer, T. / Krop, J. / Lawal, A. / Lan, L. / Rubin, R. et al. | 2014
- S529
-
P1304 HEPATITIS C GENOTYPE 2–6 VIRUSES WITH PROTEASE SUBSTITUTIONS IMPLICATED IN GENOTYPE 1 RESISTANCE SHOW COMPLEX PATTERNS OF RESISTANCE TO 8 CLINICALLY RELEVANT PROTEASE INHIBITORSJensen, S. B. / Serre, S. B. / Li, Y. P. / Humes, D. G. / Ramirez, S. / Bukh, J. / Gottwein, J. M. et al. | 2014
- S530
-
P1307 IMPACT OF HYPOTHERMIC OXYGENATED MACHINE PERFUSION (HOPE) ON IMMUNE RESPONSE IN A RODENT MODEL OF LIVER TRANSPLANTATIONSchlegel, A. / Kron, P. / Graf, R. / Clavien, P. A. / Dutkowski, P. et al. | 2014
- S532
-
P1312 SOFOSBUVIR AND DACLATASVIR FOR RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: POTENT ANTIVIRAL ACTIVITY BUT LACK OF CLINICAL BENEFIT IF TREATMENT IS GIVEN TOO LATEPellicelli, A. M. / Lionetti, R. / Montalbano, M. / Durand, C. / Ferenci, P. / DOffizi, G. / Knop, V. / Telese, A. / Lenci, I. / Andreoli, A. et al. | 2014
- S533
-
P1315 PRC1 IS UPREGULATED BY CTCF AND PROMOTES CELL PROLIFERATION IN HEPATOCELLULAR CARCINOMAZhang, B. / Ding, X. / Lv, Y. / Zhuge, Y. / Zhang, X. / Li, Y. / Wang, L. / Xu, G. / Zou, X. P. et al. | 2014
- S535
-
P1321 LONG TERM OUTCOMES AND PROGNOSTIC ANALYSIS OF SMALL HEPATOCELLULAR CARCINOMA TREATED WITH RADIOFREQUENCY ABLATION: 10 YEARS FOLLOW UP IN CHINESE PATIENTSZhang, L. / Chen, Y. / Ge, L. N. / Ren, G. Z. et al. | 2014
- S536
-
P1324 LEDIPASVIR (LDV) AND SOFOSBUVIR (SOF) COMBINATION IMPROVES PATIENT-REPORTED OUTCOMES (PRO) DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) PATIENTS: RESULTS FROM THE ION-1 CLINICAL TRIALYounossi, Z. / Stepanova, M. / Marcellin, P. / Afdhal, N. / Nader, F. / Hunt, S. et al. | 2014
- S539
-
Author index| 2014
- S591
-
Disclosures: no commercial relationships| 2014
- S597
-
Disclosures: commercial relationships| 2014
- xi
-
Contents| 2014
-
O30 ALCOHOL CONSUMPTION AND HEPATIC STEATOSIS IN THE GENERAL U.S. POPULATIONLazo, M. / Limketkai, B. / Hernaez, R. / Potter, J. J. / Clark, J. M. et al. | 2014
-
O37 EXTERNAL VALIDATION OF THE RISK-PREDICTION MODEL FOR HEPATOCELLULAR CARCINOMA [HCC] FROM THE REVEAL-HCV STUDY USING DATA FROM THE U.S. VETERANS AFFAIRS [VA] HEALTH SYSTEMMatsuda, T. / McCombs, J. / Lee, M. H. / Tonnu-Mihara, I. / Litalien, G. / Saab, S. / Hines, P. / Yuan, Y. et al. | 2014
-
O47 PEGYLATED INTERFERON-ALPHA INDUCES SUSTAINED TRANSCRIPTIONAL RESPONSE IN LIVER INFILTRATING IMMUNE CELLS BUT NOT IN HEPATOCYTES IN THE LIVER OF PATIENTS WITH CHRONIC HEPATITIS CDill, M. T. / Makowska, Z. / Trincucci, G. / Gruber, A. J. / Vogt, J. E. / Filipowicz, M. / Calabrese, D. / Krol, I. / Lau, D. T. / Terracciano, L. et al. | 2014
-
O50 THE SPECIFIC INFECTIVITY OF HEPATITIS C VIRUS IS REGULATED BY THE CATALYTIC ACTIVITY OF THE LIPID PEROXIDE SCAVENGER GLUTATHIONE PEROXIDASE 4Brault, C. / Levy, P. / Michelet, M. / Salle, A. / Pecheur, E. I. / Vericel, E. / Ivanov, A. V. / Steffen, H. M. / Odenthal, M. / Zoulim, F. et al. | 2014
-
O54 SPONTANEOUS RESOLUTION OF HEPATITIS C VIRUS INFECTION IS ASSOCIATED WITH THE PRESENCE OF ANTI-RECEPTOR ANTIBODIES IN A COHORT OF SINGLE-SOURCE OUTBREAKTawar, R. G. / Roggendorf, M. / Meisel, H. / Cosset, F. L. / Berg, T. / Zeisel, M. B. / Baumert, T. F. et al. | 2014
-
O65 HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRINLalezari, J. / Holland, L. / Glutzer, E. / Vig, P. / Elgadi, M. / Stern, J. O. / Colonno, R. / Halfon, S. / Ruby, E. / Huang, N. et al. | 2014
-
O77 PROGNOSTIC MODELS FOR MORTALITY USING THE SUCCESSIVE VALUES OF NON-INVASIVE FIBROSIS TESTS IN PATIENTS WITH CHRONIC LIVER DISEASEBertrais, S. / Boursier, J. / Oberti, F. / Fouchard-Hubert, I. / Calès, P. et al. | 2014
-
O87 FEASIBILITY AND COST ANALYSIS OF COMMUNITY BASED HEPATITIS B SCREENING PROGRAMME IN SUB-SAHARAN AFRICANayagam, S. / Shimakawa, Y. / Lemoine, M. / Njie, R. / Tamba, S. / DAlessandro, U. / Hallett, T. / Conteh, L. / Thursz, M. et al. | 2014
-
O107 ANTIVIRAL ACTIVITY OF VARIOUS INTERFERONS (IFNS) AND INFLAMMATORY CYTOKINES IN RELEVANT HEPATOCYTE MODELS OF PERSISTENT HEPATITIS B VIRUS (HBV) INFECTIONIsorce, N. / Testoni, B. / Luangsay, S. / Ait-Goughoulte, M. / Gruffaz, M. / Zannetti, C. / Hasan, U. / Henry, T. / Durantel, D. / Zoulim, F. et al. | 2014
-
P20 VALUE OF SERUM PRO-BRAIN NATURETIC PEPTIDE (pro-BNP) IN DETECTION OF CARDIAC DYSFUNCTION IN CIRRHOTIC CHILDRENEl-Shabrawi, M. H. / Fattouh, A. M. / Mahmoud, E. H. / Ahmed, W. O. et al. | 2014
-
P1051 EVALUATION OF ESTIMATED GLOMERULAR FILTRATION RATE DURING CONTINUOUS 4-YEAR TREATMENT WITH TELBIVUDINE IN PATIENTS WITH BRIDGING FIBROSIS/CIRRHOSISGane, E. J. / Lai, C. L. / Xie, Q. / Liaw, Y. F. / Thongsawat, S. / Chan, H. L. / Wang, Y. / Hwang, S. G. / Safadi, R. / Jung, M. et al. | 2014
-
P1058 LONG-TERM EFFICACY OF TENOFOVIR IN PREVIOUSLY TREATED AND NAIVE PATIENTS. RESULTS FROM THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP)Tabernero, D. / Sánchez-Tapias, J. M. / Calleja, J. L. / Moreira, V. / Manzano, M. L. / Crespo, J. / Pascasio, J. M. / Fernandez, C. M. / Aguirre, A. / Erdozain, J. C. et al. | 2014
-
P1098 DOES THE INITIAL AND REVERSIBLE DECREASE OF EGFR DURING TRIPLE THERAPY WITH TELAPREVIR REVEAL A REAL RENAL TOXICITY?Vong, C. / Rousseau, A. / Carrier, P. / Essig, M. / Debette-Gratien, M. / Jacques, J. / Legros, R. / Sautereau, D. / Loustaud-Ratti, V. et al. | 2014
-
P1100 IMPACT ON PROGNOSIS OF ANTIVIRAL EFFECT OF INTERFERON THERAPY AFTER SPLENECTOMY IN PATIENTS WITH MARKED THROMBOCYTOPENIA AND HEPATITIS C VIRUS-RELATED CIRRHOSISTamai, H. / Mori, Y. / Shingaki, N. / Maeshima, S. / Shimizu, R. / Nuta, J. / Maeda, Y. / Moribata, K. / Muraki, Y. / Deguchi, H. et al. | 2014
-
P1124 EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON ALFA-2a PLUS RIBAVIRIN IN PRISON INMATES WITH OR WITHOUT PERSONALITY DISORDER. SUBANALYSIS OF THE PERSEO STUDYAndres, M. / Anton, J. J. / de la Hoya, P. S. / de Juan, J. / Faraco, I. et al. | 2014
-
P1135 ADDITION OF TELAPREVIR OR BOCEPREVIR TO PEG-RIB THERAPY INCREASES THE RISK OF INFECTIONS IN PATIENTS WITH HEPATITIS C-RELATED CIRRHOSIS (HCV-CH): A COMPARATIVE STUDYLondoño, M. C. / Perelló, C. / Cabezas, J. / Carrión, J. A. / Lens, S. / Mariño, Z. / Rodríguez, R. / Menéndez, S. / Crespo, J. / Calleja, J. L. et al. | 2014
-
P1167 rs12979860 IL28B GENOTYPE IS ASSOCIATED WITH ADVANCED FIBROSIS IN HCV GENOTYPE 1-INFECTED EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE INTERNATIONAL GEN-C STUDYMangia, A. / De Ledinghen, V. / Bailly, F. / Brahm, J. / Keiss, J. / Valantinas, J. / Rasmann, N. / Riachi, G. / Messinger, D. / Caputo, A. et al. | 2014
-
P1174 THE NOVEL ss469415590 POLYMORPHISM PREDICTS RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS TYPE 1 INFECTIONCovolo, L. / Bibert, S. / Donato, F. / Bochud, P. Y. / Lagging, M. / Negro, F. / Fattovich, G. et al. | 2014
-
P1179 SPLENIC ARTERY HEMODYNAMIC CHANGES ARE AFFECTED BY PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS CAbdel-Khalek, E. E. / Elaskalany, H. M. / Amer, T. et al. | 2014
-
P1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTIONForns, X. / Samuel, D. / Mutimer, D. / Fagiouli, S. / Navasa, M. / Agarwal, K. / Berenguer, M. / Colombo, M. / Herzer, K. / Nevens, F. et al. | 2014
-
P1201 UTILITY OF SERUM MARKERS AND TRANSIENT ELASTOGRAPHY TO IDENTIFY SERIOUS ADVERSE EFFECTS DURING ANTIVIRAL THERAPY IN HCV INFECTED CIRRHOTIC PATIENTS. A MULTICENTER STUDYPuigvehí, M. / Londoño, M. C. / Morillas, R. M. / Miquel, M. / Gallego, A. / Lens, S. / Baiges, A. / Vergara, M. / Torras, X. / Planas, R. et al. | 2014
-
P1216 EFFICACY AND SAFETY OF SIMEPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY IN PATIENTS WITH HCV GENOTYPE 1 – COMPARISON WITH TELAPREVIR PLUS PEG-INTERFERON/RIBAVIRIN THERAPY AND PEG-INTERFERON/RIBAVIRIN THERAPYNakajima, T. / Kimura, M. / Arakawa, T. / Kuwata, Y. / Ozeki, I. / Sato, T. / Ohmura, T. / Hige, S. / Karino, Y. / Toyota, J. et al. | 2014
-
P1268 IMPACT OF DIET ON GUT MICROBIOTA AND LIVER PHENOTYPE IN CFTR KNOCKOUT MICEDebray, D. / Brot, L. / El Mourabit, H. / Barbu, V. / Rainteau, D. / Sokol, H. / Housset, C. et al. | 2014
-
P1310 HEPATOCELLULAR CARCINOMA (HCC) INVADING PORTAL VENOUS SYSTEM IN CIRRHOSIS: 7 YEAR RESULTS OF PERCUTANEOUS RADIOFREQUENCY ABLATION OF HCC AND MAIN PORTAL VEIN TUMOR THROMBUS (MPVTT)Giorgio, A. / Calisti, G. / Coppola, C. / Scarano, F. / Scognamiglio, U. / Farella, N. / Montesarchio, L. / de Stefano, G. / Gatti, P. / Giorgio, V. et al. | 2014
-
P48 EGF/EGFR AXIS CONTRIBUTES TO THE PROGRESSION OF CHOLANGIOCARCINOMA THROUGH THE INDUCTION OF AN EPITHELIAL–MESENCHYMAL TRANSITIONClapéron, A. / Mergey, M. / Ho-Bouldoires, T. H. / Vignjevic, D. / Wendum, D. / Chrétien, Y. / Merabtene, F. / Frazao, A. / Paradis, V. / Housset, C. et al. | 2014
-
P61 avb6 INTEGRIN ANTAGONISM IMPEDES SPHEROID FORMATION OF TUMOR CELLS IN VITRO AND CHOLANGIOCARCINOMA PROGRESSION IN VIVOPatsenker, E. / Schneider, V. / Ledermann, M. / Saegesser, H. / Keogh, A. / Stickel, F. et al. | 2014
-
P67 PAF-RECEPTOR INHIBITORS HAVE AN ANTI-PROLIFERATIVE EFFECT ON HEPATOCELLULAR CARCINOMA CELLSTarocchi, M. / Marroncini, G. / Polvani, S. / Mello, T. / Tempesti, S. / Ceni, E. / Galli, A. et al. | 2014
-
P87 DETECTION OF CIRCULATING TUMOUR CELLS (CTCS) IN HEPATOCELLULAR (HCC) CANCER PATIENTS USING THE IMAGESTREAMOgle, L. / Jamieson, D. / ODonnell, R. / Dent, B. / Boddy, A. / Curtin, N. / Plummer, R. / Reeves, H. et al. | 2014
-
P86 IMPACT OF GLUTATHIONE PEROXIDASE 4 OVEREXPRESSION ON HEPATOCELLULAR CARCINOMA: AN IN VITRO AND IN VIVO STUDYRohr-Udilova, N. / Stoiber, D. / Bauer, E. / Li, W. / Seif, M. / Hayden, H. / Stolze, K. / Brigelius-Flohe, R. / Eferl, R. / Peck-Radosavljevic, M. et al. | 2014
-
P90 AUTOANTIBODY SIGNATURES AS BIOMARKER FOR CHOLANGIOCARCINOMA DEFINED BY SEROLOGICAL PROTEOME ANALYSISMustafa, M. Z. / Duclos-Vallee, J. C. / Ballot, E. et al. | 2014
-
P101 HISTONE VARIANT macroH2A1 PROTECTS AGAINST 5-AZA-2′-DEOXYCYTIDINE INDUCED HEPATOCYTE SENESCENCEBorghesan, M. / Mazza, T. / Fusilli, C. / Faulkes, C. / Pazienza, V. / Vinciguerra, M. et al. | 2014
-
P105 ACTIVATION OF SENESCENT GENES IN CHRONIC AND ACUTE-ON-CHRONIC LIVER FAILURE RAT BRAINSOria, M. / Andreola, F. / Garcia, R. / Jalan, R. et al. | 2014
-
P130 HEPATITIS C VIRUS PREVENTS IL-1β-INDUCED EXPRESSION OF LIPOCALIN2 VIA SUPPRESSION OF IκBζSpitzley, S. / Bartenschlager, R. / Häussinger, D. / Bode, J. G. et al. | 2014
-
P175 ASSOCIATION OF METHYLATED HISTONES AND DNA METHYLASES WITH HEPATITIS B VIRUS COVALENTLY CLOSED CIRCULAR DNA AND THEIR ASSOCIATION WITH HEPATITIS B VIRUS REPLICATIONWong, D. K. / Lin, J. S. / Huang, F. Y. / Tsoi, O. / Seto, W. K. / Fung, J. / Lai, C. L. / Yuen, M. F. et al. | 2014
-
P202 EVALUATION OF A HEPATITIS C VIRUS THERAPEUTIC VACCINE CANDIDATE IN WILDTYPE- AND HCV-TRANSGENIC MICEHolmström, F. / Sällberg, M. / Ahlén, G. / Frelin, L. et al. | 2014
-
P229 HCV GENOTYPE 2 AND 1 INTER-GENOTYPE RECOMBINATION VARIANTS ACCOUNT FOR DISCORDANCE BETWEEN LIPA-BASED HCV GENOTYPING AND NS5B SEQUENCINGHedsko, C. / Doehle, B. / Chodavarapu, K. / Gontcharova, V. / Brainard, D. / Symonds, W. T. / Miller, M. D. / Svarovskaia, E. / Mo, H. et al. | 2014
-
P293 OBESITY DEPRESSES THE ANTI-INFLAMMATORY HSP70 PATHWAY CONTRIBUTING TO THE PROGRESSION OF NAFLD IN OBESE PATIENTSMarroni, N. P. / Di Naso, F. C. / Fillmann, H. S. / Maggioni, L. / Padoin, A. V. / Ramos, R. J. / Mottin, C. C. / Porto, R. R. / Bittencourt, A. B. / de Bittencourt, P. I. et al. | 2014
-
P305 BLOCKADE OF PD1/TIM3 RESTORES FAVOURABLE IFNγ/IL10 IMMUNE AXIS IN ALCOHOL-RELATED LIVER DISEASEMarkwick, L. J. / Riva, A. / Ryan, J. M. / Cooksley, H. / Tranah, T. H. / Vijay, G. K. / Vergis, N. / Thursz, M. / Evans, A. / Williams, R. et al. | 2014
-
P330 ACTIVATION OF INTERFERON AND NF-κB PATHWAYS IN EARLY HUMAN ALCOHOLIC LIVER DISEASE DEVELOPMENTStärkel, P. / Lanthier, N. / De Saeger, C. / Sempoux, C. / Leclercq, I. A. / Horsmans, Y. et al. | 2014
-
P336 HEPATOCYTES IMPROVE THEIR DRUG METABOLIC ACTIVITY WITH THE PRESENCE OF ENDOTHELIAL CELLS IN AN IN VITRO HEPATIC CO-CULTURE MODEL OF ACETAMINOPHEN TOXICITYNavarro, M. / Nelson, L. / Treskes, P. / Hayes, P. / Samuel, K. / Plevris, J. et al. | 2014
-
P338 ROLE OF ACID SPHINGOMYELINASE IN APAP-INDUCED LIVER INJURYBaulies, A. / Nuñez, S. / Ribas, V. / Martinez, L. / Kaplowitz, N. / García-Ruiz, C. / Fernández-Checa, J. C. et al. | 2014
-
P348 REGULATION OF CHOLANGIOCYTE PROLIFERATION BY THE miR-125B/HDC/HA/VEGF AXIS IN THE MDR2 MOUSE MODEL OF PRIMARY SCLEROSING CHOLANGITISHan, Y. / Meng, F. / Hargrove, L. / Graf, A. / Kennedy, L. / Francis, H. et al. | 2014
-
P356 CREMa TRANSGENE-ASSOCIATED IMMUNE RESPONSE INHIBITS THE PROGRESSION OF CHRONIC INFLAMMATORY LIVER DISEASEHermanns, N. / Cubero, F. J. / Mohs, A. / Ohl, K. / Al Masaoudi, M. / Tenbrock, K. / Trautwein, C. et al. | 2014
-
P384 RETINOIC ACID AMPLIFIES THE FXR-DEPENDENT FGF19 GENE EXPRESSION IN HUMAN ENTEROCYTE-LIKE HT-29 CELLS BY A BI-PHASIC MECHANISMJahn, D. / Sutor, D. / Schmitt, J. / Geier, A. et al. | 2014
-
P388 NK AND NKT CELLS EXPRESSING CD161 – A C-TYPE LECTIN CONFERRING REGULATORY PROPERTIES – ARE MARKEDLY REDUCED IN AUTOIMMUNE HEPATITISNeo, J. Z. / Huang, X. / Xystrakis, E. / Longhi, M. S. / Jassem, W. / Mieli-Vergani, G. / Vergani, D. / Ma, Y. et al. | 2014
-
P447 RELATIONSHIP BETWEEN ECHOCARDIOGRAPHIC ALTERATIONS AND NT-proBNP PLASMATIC LEVELS IN CIRRHOTIC PATIENTSEspinosa, M. D. / Nogueras, F. / López Garrido, M. A. / Comino, A. / Bueno, P. / De Teresa, J. et al. | 2014
-
P452 MORTALITY ASSOCIATED WITH HEPATIC ENCEPHALOPATHY IN PATIENTS WITH SEVERE LIVER DISEASEMorgan, C. L. / Jenkins-Jones, S. / Radwan, A. / Conway, P. / Reynolds, A. / Currie, C. J. et al. | 2014
-
P454 ABDOMINAL CTSCAN PREDICTS CLINICAL OUTCOME IN PATIENTS WITH ALCOHOLIC HEPATITISSpahr, L. / Terraz, S. / Breguet, R. / Giostra, E. / Boudabbous, S. / Becker, C. D. et al. | 2014
-
P461 UTILITY OF BISPECTRAL INDEX MONITORING FOR ASSESSMENT OF PRESENCE AND SEVERITY OF OVERT AND MINIMAL HEPATIC ENCEPHALOPATHY BEFORE AND AFTER TREATMENT IN PATIENTS WITH CIRRHOSISJindal, A. / Sharma, B. C. / Sachdeva, S. / Chawla, R. / Srivastava, S. / Maharshi, S. et al. | 2014
-
P544 CLINICAL USEFULLNESS OF PRIMOVIST-MRI ON INITIAL STAGING WORKUP IN HEPATOCELLULAR CARCINOMA PATIENTS WHO ARE CANDIDATES FOR CURATIVE TREATMENTS ON LIVER DYNAMIC CTJin, Y. J. / Lee, J. W. / Chung, H. J. / Kim, Y. S. / Cho, S. G. / Jeon, Y. S. et al. | 2014
-
P554 ASSESSMENT OF PROGNOSIS IN HEPATOCELLULAR CARCINOMA USING A BIOMARKER BASED APPROACH: VALIDATION AND EXTENSION OF THE BALAD MODELFox, R. / Berhane, S. / Teng, M. / Cox, T. / Tada, T. / Toyoda, H. / Kumada, T. / Kagebayashi, C. / Satomura, S. / Johnson, P. et al. | 2014
-
P564 ‘LATE WASHOUT’ ON THE HEPATOSPECIFIC PHASE OF Gd-BOPTA MRI IN THE CHARACTERISATION OF ARTERIAL-ENHANCING HCCS LACKING WASHOUT ON THE PORTAL VENOUS AND EQUILIBRIUM PHASESCortis, K. / Liotta, R. / Miraglia, R. / Caruso, S. / Tuzzolino, F. / Luca, A. et al. | 2014
-
P575 DIAGNOSTIC SIGNIFICANCE OF HEPATIC VENOUS PRESSURE GRADIENT IN THE PREDICTION OF HEPATOCELLULAR CARCINOMASuk, K. T. / Bang, C. S. / Lee, Y. S. / Lee, Y. H. / Kim, D. J. et al. | 2014
-
P586 APPEARANCE OF COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA IN CIRRHOSIS AT CONTRAST ENHANCED IMAGING TECHNIQUESSagrini, E. / Iavarone, M. / Vavassori, S. / Stefanini, F. / Maggioni, M. / Pettinari, I. / Pecorelli, A. / Colombo, M. / Bolondi, L. / Piscaglia, F. et al. | 2014
-
P590 RELATION OF HCV INDUCED INSULIN RESISTANCE AND HEPATOCELLULAR CARCINOMA: ROLE OF MDR1 GENE c.335T>C AND c.3073A>C SNPSElsamanoudy, A. Z. / Atwa, A. A. / Elalfy, H. / Metwali, A. H. et al. | 2014
-
P603 DIFFERENCES IN THE HEPATOCYTE POLYPLOIDY CORRESPOND WITH DIFFERENCES IN INSULIN BINDING AND DIVERGING METABOLIC FUNCTIONSBartolomé Rodríguez, M. M. / Kreutz, C. / Follo, M. / Timmer, J. / Blum, H. et al. | 2014
-
P635 INVOLVEMENT OF HEAT SHOCK PROTEIN 47 IN SCHISTOSOMA JAPONICUM-INDUCED HEPATIC FIBROSIS IN MICETao, R. / Huang, J. Q. / Li, L. / Ma, K. / Fan, X. X. / Jiao, Y. T. / Ning, Q. et al. | 2014
-
P638 MOLECULAR MODELING AND ANALYSIS OF HEPATITIS E VIRUS (HEV) PAPAIN-LIKE CYSTEINE PROTEASEParvez, M. K. et al. | 2014
-
P641 HIGH PREVALENCE OF HEPATITIS D VIRUS (HDV) IN VIETNAMESE HBsAg-POSITIVE PATIENTS AND A NATURAL INTER-GENOTYPIC RECOMBINANT OF HDV-GENOTYPES 1 AND 2Bui, T. S. / Ratsch, B. A. / Nguyen, M. H. / Velavan, T. P. / Bock, C. T. et al. | 2014
-
P640 GENE MUTATION DETECTION ANALYSIS OF SWINE HEPATITIS E VIRUS PROPAGATED IN THE PRIMARY-CULTURED HUMAN HEPATOCYTESOshiro, Y. / Yasue, H. / Ideno, S. / Hattori, S. / Sakai, K. / Osari, S. / Takeuchi, K. / Nagata, K. / Ohkohchi, N. et al. | 2014
-
P702 HEV INFECTION IS A FREQUENT CAUSE (20%) OF ELEVATED TRANSAMINASES IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: RESULTS OF A FRENCH MONOCENTRIC PROSPECTIVE STUDYFournier, S. / Guillaume, M. / Luxembourger, C. / Abravanel, F. / Bagheri, H. / Wargny, M. / Bureau, C. / Vinel, J. P. / Cantagrel, A. / Péron, J. M. et al. | 2014
-
P720 HEALTH-RELATED QUALITY OF LIFE (HRQL) AND PATIENT-REPORTED OUTCOMES (PROS) ASSESSMENT IN CHRONIC HEPATITIS C (CH-C) TREATED WITH SOFOSBUVIR (SOF) AND RIBAVIRIN (RBV): THE VALENCE STUDYYounossi, Z. M. / Stepanova, M. / Zeuzem, S. / Reesink, H. W. / Weiland, O. / Nader, F. / Hunt, S. L. et al. | 2014
-
P731 CANNABINOID RECEPTOR 2-63 QQ VARIANT IS ASSOCIATED WITH PERSISTENTLY NORMAL AMINOTRANSFERASE SERUM LEVELS IN CHRONIC HEPATITIS CCoppola, N. / Zampino, R. / Sagnelli, C. / Bellini, G. / Marrone, A. / Stanzione, M. / Capoluongo, N. / Boemio, A. / Minichini, C. / Adinolfi, L. E. et al. | 2014
-
P750 SPONTANEOUS HCV CLEARANCE IN HIV PATIENTS WITH CHRONIC HEPATITIS C BEARING FAVORABLE IL28B ALLELES ON ANTIRETROVIRAL THERAPYVispo, E. / Barreiro, P. / Fernandez-Montero, J. V. / Labarga, P. / de Mendoza, C. / Treviño, A. / Soriano, V. et al. | 2014
-
P770 LOWER UPTAKE OF HCV TREATMENT THAN HIV TREATMENT IN HIV/HCV CO-INFECTED PATIENTSStenkvist, J. / Weiland, O. / Sönnerborg, A. / Blaxhult, A. / Falconer, K. et al. | 2014
-
P781 SPONTANEOUS CLEARANCE RATES INCREASE WITH HCV REINFECTION EPISODE IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN (MSM) INDEPENDENT OF HCV SUBTYPEIngiliz, P. / Boesecke, C. / Martin, T. C. / Mauss, S. / Rodger, A. / Mandorfer, M. / Baumgarten, A. / Stellbrink, H. J. / Bhagani, S. / Rockstroh, J. K. et al. | 2014
-
P788 RANDOMIZED TRIAL OF INTEGRATED CARE TO PROMOTE DIRECT ACTING ANTIVIRAL TREATMENT AMONG HIGH RISK HEPATITIS C PATIENTS WITH PSYCHIATRIC AND SUBSTANCE USE DISORDERSHo, S. B. / Groessl, E. J. / Liu, L. / Sanchez, C. M. / Wasil, M. M. / Robinson, S. K. et al. | 2014
-
P789 EARLY VIROLOGICAL RESPONSE IS THE MAIN PREDICTOR OF VIRAL ERADICATION IN HCV HAEMODIALYSIS PATIENTS TREATED WITH PEGYLATED INTERFERON PLUS RIBAVIRINRendina, M. / Tucci, A. / Castellaneta, A. / Castellaneta, N. M. / Zappimbulso, M. / Chiala, C. / Leandro, G. / di Leo, A. et al. | 2014
-
P792 EFFECT OF URSODEOXYCHOLIC ACID OR URSODEOXYCHOLIC ACID COMBINED WITH LOSARTAN FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITISStilidi, E. I. / Klyaritskay, I. L. et al. | 2014
-
P812 NOX2-GENERATED OXIDATIVE STRESS IS INCREASED IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE INDEPENDENTLY FROM METABOLIC SYNDROMEDel Ben, M. / Polimeni, L. / Carnevale, R. / Bartimoccia, S. / Baratta, F. / Pastori, D. / Calabrese, C. / Salzano, D. / Angelico, F. et al. | 2014
-
P817 EARLY MENOPAUSAL STATUS IS ASSOCIATED WITH THE SEVERITY OF LIVER FIBROSIS IN ITALIAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASEPetta, S. / Vanni, E. / Valenti, L. / Miele, L. / Bianchini, M. / Fracanzani, A. L. / Bugianesi, E. / Craxì, A. / Fargion, S. / Grieco, A. et al. | 2014
-
P826 HEPCIDIN LEVELS IN PATIENTS WITH NAFLD WITH OR WITHOUT HYPERFERRITINEMIA AND/OR DYSMETABOLIC IRON OVERLOADMarmur, J. / Beshara, S. / Eggertsen, G. / Albiin, N. / Danielsson, O. / Hultcrantz, R. / Stål, P. et al. | 2014
-
P839 HANDLING AN ORAL GLUCOSE LOAD AFTER A 4 WEEK ORAL HIGH FRUCTOSE CHALLENGE AND ITS IMPACT ON FETUIN-AKienbacher, C. / Lorant, D. / Traussnigg, S. / Haslacher, H. / Steindl-Munda, P. / Krebs, M. / Schernthaner, G. H. / Trauner, M. et al. | 2014
-
P842 A STUDY OF RISK FACTORS ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE [NAFLD] IN INDIANSSingh, S. P. / Misra, D. / Singh, A. / Misra, B. / Pati, G. K. / Panigrahi, M. K. / Kar, S. K. / Meher, C. / Agrawal, O. et al. | 2014
-
P879 CIRCULATING miRNA-122/let-7d RATIO, HEPATITIS C VIRUS LOAD AND FIBROSING CHOLESTATIC HCV RECURRENCE AFTER LIVER TRANSPLANTATIONFinkenstedt, A. / Lechner, S. / Baumgartner, N. / Pratschke, J. / Graziadei, I. / Vogel, W. / Zoller, H. et al. | 2014
-
P899 MELD-BASED ALLOCATION SYSTEM FOR LIVER TRANSPLANTATION IS NOT EQUITABLE USING THE CURRENT HEPATOCELLULAR CARCINOMA EXCEPTION POLICYLledó, J. L. / Del Campo, S. / Tellez, L. / García, M. / Bárcena, R. / Albillos, A. et al. | 2014
-
P902 TELAPREVIR-TRIPLE THERAPY OF RECURRENT HCV GENOTYPE 1 (G1) INFECTION AFTER LIVER TRANSPLANTATION (LTX): SVR 24 RESULTSWerner, C. R. / Egetemeyr, D. P. / Nadalin, S. / Königsrainer, A. / Malek, N. P. / Lauer, U. M. / Berg, C. P. et al. | 2014
-
P933 ONCE-DAILY ORAL LUSUTROMBOPAG, ALTERNATIVE TO PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING RADIOFREQUENCY ABLATION: RESULTS FROM A PHASE 2B, RANDOMIZED, DOUBLE-BLIND STUDYIzumi, N. / Tateishi, R. / Seike, M. / Kudo, M. / Tamai, H. / Kawazoe, S. / Tanaka, K. / Kurokawa, M. / Osaki, Y. / Yamamoto, K. et al. | 2014
-
P938 BACTERIAL DNA IN NON-LEUKOCYTIC ASCITES, IDENTIFICATION OF RISK FACTORSEngelmann, C. / Krohn, S. / Prywerek, D. / Zeller, K. / Deichsel, D. / Fischer, J. / Böhlig, A. / Böhm, S. / Berg, T. et al. | 2014
-
P936 RELAXIN MODULATES RENAL VASCULAR ENDOTHELIAL DYSFUNCTION IN EXPERIMENTAL CIRRHOSIS: IMPLICATIONS FOR THE TREATMENT OF HEPATORENAL SYNDROMESnowdon, V. K. / Hadoke, P. W. / Mungall, W. / Kendall, T. / Iredale, J. P. / Fallowfield, J. A. et al. | 2014
-
P939 NGAL IN PATIENTS WITH LIVER CIRRHOSIS: RELATION TO PATIENT CHARACTERISTICS AND KINETICSHurry, P. / Hjelm Poulsen, J. / Bendtsen, F. / Møller, S. et al. | 2014
-
P948 TERLIPRESSIN INDUCES HYPONATREMIA IN A SUBGROUP OF CIRRHOTIC PATIENTS WITH ACUTE VARICEAL BLEEDING OR HEPATORENAL SYNDROME AND IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMENguyen-Tat, M. / Götz, E. / Heeren, J. / Sivanathan, V. / Ploch, P. / Sollinger, D. / Wörns, M. / Galle, P. R. / Marquardt, J. U. et al. | 2014
-
P966 EVALUATION OF THE PREVENTIVE EFFECT OF LOW DOSE ENOXAPARIN, PENTOXIFYLLINE AND URSODEOXYCHOLIC ACID TO RADIATION INDUCED LIVER TOXICITY IN A PROSPECTIVE RANDOMIZED TRIALSeidensticker, M. / Seidensticker, R. / Damm, R. / Mohnike, K. / Pech, M. / Sangro, B. / Hass, P. / Wust, P. / Kropf, S. / Gademann, G. et al. | 2014
-
P986 MANAGEMENT OF HCC BY TRANSARTERIAL CHEMOEMBOLIZATION CONVENTIONAL AND BEADS DOXORUBICINCiria, V. / Ferrer, M. T. / Giraldez, . / Sousa, J. M. / Nacarino, V. / Iglesias, . / Peiró, J. / Pascasio, J. M. et al. | 2014
-
P997 NON SUPERIORITY OF DRUG-ELUTING BEADS WITH RESPECT TO CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION FOR THE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA: A PROPENSITY SCORE ANALYSISFacciorusso, A. / Sposito, C. / Mariani, L. / Spreafico, C. / Marchianò, A. / Bhoori, S. / Barone, M. / Mazzaferro, V. et al. | 2014
-
P1028 NON-INVASIVE SCORE SYSTEM FOR FIBROSIS (NISF) IN CHRONIC LIVER DISEASE: A NEW MODEL COMBINING BIOCHEMICAL, ELASTOGRAPHIC AND ULTRASOUND DATAGaia, S. / Campion, D. / Spandre, M. / Cantamessa, A. / Brunello, F. / Evangelista, A. / Cosso, L. / Carucci, P. / Rolle, E. / Ciccone, G. et al. | 2014